WO2019185016A1 - 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 - Google Patents
含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 Download PDFInfo
- Publication number
- WO2019185016A1 WO2019185016A1 PCT/CN2019/080412 CN2019080412W WO2019185016A1 WO 2019185016 A1 WO2019185016 A1 WO 2019185016A1 CN 2019080412 W CN2019080412 W CN 2019080412W WO 2019185016 A1 WO2019185016 A1 WO 2019185016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- optionally
- fluorine
- hydrogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 108090000565 Capsid Proteins Proteins 0.000 title claims abstract description 26
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 26
- 239000003112 inhibitor Substances 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 105
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- 239000000651 prodrug Substances 0.000 claims abstract description 53
- 229940002612 prodrug Drugs 0.000 claims abstract description 53
- 239000012453 solvate Substances 0.000 claims abstract description 50
- 239000002207 metabolite Substances 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 121
- -1 hydrate Substances 0.000 claims description 100
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 76
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 73
- 229910052731 fluorine Inorganic materials 0.000 claims description 70
- 239000011737 fluorine Substances 0.000 claims description 70
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 66
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 53
- 150000002431 hydrogen Chemical class 0.000 claims description 52
- 125000001153 fluoro group Chemical group F* 0.000 claims description 48
- 239000000460 chlorine Chemical group 0.000 claims description 37
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 36
- 229910052801 chlorine Inorganic materials 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 34
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 17
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 16
- 230000008901 benefit Effects 0.000 claims description 15
- 125000001246 bromo group Chemical group Br* 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 34
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 181
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 144
- 238000006243 chemical reaction Methods 0.000 description 105
- 239000000203 mixture Substances 0.000 description 77
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 68
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 241000700721 Hepatitis B virus Species 0.000 description 19
- 239000005457 ice water Substances 0.000 description 19
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 239000007821 HATU Substances 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 0 *c1cc(O)cc(*)c1* Chemical compound *c1cc(O)cc(*)c1* 0.000 description 9
- HHTRAISBAAXRKZ-UHFFFAOYSA-N 5-amino-2-fluorobenzonitrile Chemical compound NC1=CC=C(F)C(C#N)=C1 HHTRAISBAAXRKZ-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229910021642 ultra pure water Inorganic materials 0.000 description 7
- 239000012498 ultrapure water Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000001853 liver microsome Anatomy 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- VLVCERQEOKPRTG-DKWTVANSSA-N (2s)-1,1,1-trifluoropropan-2-amine;hydrochloride Chemical group Cl.C[C@H](N)C(F)(F)F VLVCERQEOKPRTG-DKWTVANSSA-N 0.000 description 4
- GCXROLAHZMJNSE-UHFFFAOYSA-N 2-[4-[(3-cyano-4-fluorophenyl)carbamoyl]-1-methylpyrrol-2-yl]-2-oxoacetic acid Chemical compound Cn1cc(cc1C(=O)C(O)=O)C(=O)Nc1ccc(F)c(c1)C#N GCXROLAHZMJNSE-UHFFFAOYSA-N 0.000 description 4
- HECZPOCJWCHBHK-UHFFFAOYSA-N 4-methyloxan-4-amine Chemical compound CC1(N)CCOCC1 HECZPOCJWCHBHK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- UNIFRBWRVMAKDB-UHFFFAOYSA-N methyl 1-methylpyrrole-3-carboxylate Chemical compound COC(=O)C=1C=CN(C)C=1 UNIFRBWRVMAKDB-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- GBVGOAXSVZTDFI-UHFFFAOYSA-N 2-(4-ethoxycarbonyl-1,3,5-trimethylpyrrol-2-yl)-2-oxoacetic acid Chemical compound CCOC(=O)c1c(C)c(C(=O)C(O)=O)n(C)c1C GBVGOAXSVZTDFI-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- KEYBLBUGXCHLBX-UHFFFAOYSA-N 3,3-difluoro-1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CC(F)(F)C1 KEYBLBUGXCHLBX-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710142246 External core antigen Proteins 0.000 description 3
- VIIVEBKQNBLVGD-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-[(3-methyloxetan-3-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1(C)COC1 VIIVEBKQNBLVGD-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- PUJICPRRQXQDOM-UHFFFAOYSA-N ethyl 1,2,4-trimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C(C)=CN(C)C=1C PUJICPRRQXQDOM-UHFFFAOYSA-N 0.000 description 3
- QWSFDUPEOPMXCV-UHFFFAOYSA-N ethyl 2,4-dimethyl-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C(C)=CNC=1C QWSFDUPEOPMXCV-UHFFFAOYSA-N 0.000 description 3
- LFZCEYSEXFICKB-UHFFFAOYSA-N ethyl 5-(2-ethoxy-2-oxoacetyl)-1,2-dimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1cc(C(=O)OCC)c(C)n1C LFZCEYSEXFICKB-UHFFFAOYSA-N 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- DVQGUDGJBKDLLA-UHFFFAOYSA-N 1,2,4-trimethyl-5-[2-[(3-methyloxetan-3-yl)amino]-2-oxoacetyl]-N-(3,4,5-trifluorophenyl)pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2cc(F)c(F)c(F)c2)c(C)n(C)c1C(=O)C(=O)NC1(C)COC1 DVQGUDGJBKDLLA-UHFFFAOYSA-N 0.000 description 2
- MIKOZAZRIJWWRE-UHFFFAOYSA-N 1,2,4-trimethylpyrrole-3-carboxylic acid Chemical compound CC1=CN(C)C(C)=C1C(O)=O MIKOZAZRIJWWRE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KSCVQJSNYDFHOT-UHFFFAOYSA-N 1-amino-3,3-difluorocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC(F)(F)C1 KSCVQJSNYDFHOT-UHFFFAOYSA-N 0.000 description 2
- AJJOSJKCCQBIPJ-RXMQYKEDSA-N 1-methyl-5-[2-oxo-2-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxylic acid Chemical compound C[C@@H](NC(=O)C(=O)c1cc(cn1C)C(O)=O)C(F)(F)F AJJOSJKCCQBIPJ-RXMQYKEDSA-N 0.000 description 2
- AJJOSJKCCQBIPJ-YFKPBYRVSA-N 1-methyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxylic acid Chemical compound C[C@H](NC(=O)C(=O)c1cc(cn1C)C(O)=O)C(F)(F)F AJJOSJKCCQBIPJ-YFKPBYRVSA-N 0.000 description 2
- ZBGBMYWHRGIAPW-UHFFFAOYSA-N 2-[(3-formylthiophen-2-yl)methylidene]propanedinitrile Chemical group O=CC=1C=CSC=1C=C(C#N)C#N ZBGBMYWHRGIAPW-UHFFFAOYSA-N 0.000 description 2
- QGCMERGZXSHVDF-UHFFFAOYSA-N 2-[4-[(3-cyano-4-fluorophenyl)carbamoyl]-3-fluoro-1,5-dimethylpyrrol-2-yl]-2-oxoacetic acid Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(F)c(C(=O)C(O)=O)n1C QGCMERGZXSHVDF-UHFFFAOYSA-N 0.000 description 2
- VCZWEAPBFXANAK-UHFFFAOYSA-N 2-chloro-N-(3-cyano-4-fluorophenyl)-5-[2-[(3-hydroxy-1-methylcyclobutyl)amino]-2-oxoacetyl]-1,4-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(Cl)n(C)c1C(=O)C(=O)NC1(C)CC(O)C1 VCZWEAPBFXANAK-UHFFFAOYSA-N 0.000 description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
- WBMPNWAJZXILJR-UHFFFAOYSA-N 3-(trifluoromethyl)oxetan-3-amine;hydrochloride Chemical compound Cl.FC(F)(F)C1(N)COC1 WBMPNWAJZXILJR-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NPFYLUDWMOOWFN-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-1-methylpyrrole-3-carboxylic acid Chemical compound Cn1cc(cc1C(=O)C(=O)NC(C)(C)C)C(O)=O NPFYLUDWMOOWFN-UHFFFAOYSA-N 0.000 description 2
- OKDRVKQVVLTNQK-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC(C)(C)C OKDRVKQVVLTNQK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HGTOOBPUMBDFPH-GASCZTMLSA-N C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@@H](C1)O)=O)C)C Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@@H](C1)O)=O)C)C HGTOOBPUMBDFPH-GASCZTMLSA-N 0.000 description 2
- HGTOOBPUMBDFPH-SHTZXODSSA-N C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@H](C1)O)=O)C)C Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@H](C1)O)=O)C)C HGTOOBPUMBDFPH-SHTZXODSSA-N 0.000 description 2
- RJTAQSDAUPRVBQ-UHFFFAOYSA-N CCOC(=O)C(=C=C)C(C)O Chemical compound CCOC(=O)C(=C=C)C(C)O RJTAQSDAUPRVBQ-UHFFFAOYSA-N 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JOCQDYBKZJKMCF-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-(oxetan-3-ylamino)-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1COC1 JOCQDYBKZJKMCF-UHFFFAOYSA-N 0.000 description 2
- NRMYRIIWJRUGNP-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-[(3-methyloxolan-3-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1(C)CCOC1 NRMYRIIWJRUGNP-UHFFFAOYSA-N 0.000 description 2
- QKHNPFYGAXMSON-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-oxo-2-(oxolan-3-ylamino)acetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1CCOC1 QKHNPFYGAXMSON-UHFFFAOYSA-N 0.000 description 2
- DTUVHEVJDTWNEG-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-oxo-2-(prop-2-ynylamino)acetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NCC#C DTUVHEVJDTWNEG-UHFFFAOYSA-N 0.000 description 2
- ALPXGYHAXUPRQL-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C=C1C)C)C ALPXGYHAXUPRQL-UHFFFAOYSA-N 0.000 description 2
- JDJNMRWMFYYPRU-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,4-dimethylpyrrole-3-carboxamide Chemical compound Cc1cn(C)cc1C(=O)Nc1ccc(F)c(c1)C#N JDJNMRWMFYYPRU-UHFFFAOYSA-N 0.000 description 2
- WWAWUVAIITZWQB-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1-methylpyrrole-3-carboxamide Chemical compound Cn1ccc(c1)C(=O)Nc1ccc(F)c(c1)C#N WWAWUVAIITZWQB-UHFFFAOYSA-N 0.000 description 2
- IBGUFFGDNPORSV-VIFPVBQESA-N N-(3-cyano-4-fluorophenyl)-4-fluoro-1,2-dimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxamide Chemical compound C[C@H](NC(=O)C(=O)c1c(F)c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n1C)C(F)(F)F IBGUFFGDNPORSV-VIFPVBQESA-N 0.000 description 2
- DETRBETYRASUMV-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-2-oxoacetyl]-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC(C)(C)CO DETRBETYRASUMV-UHFFFAOYSA-N 0.000 description 2
- NZNMRDQEUMPFHJ-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-5-[2-[(3-hydroxy-1-methylcyclobutyl)amino]-2-oxoacetyl]-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1(C)CC(O)C1 NZNMRDQEUMPFHJ-UHFFFAOYSA-N 0.000 description 2
- MGPBFZNYRCZYAZ-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-5-[2-[[1-(hydroxymethyl)cyclopropyl]amino]-2-oxoacetyl]-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1(CO)CC1 MGPBFZNYRCZYAZ-UHFFFAOYSA-N 0.000 description 2
- OUOGNXQMLHDWNG-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-5-[2-[[3,3-difluoro-1-(methylcarbamoyl)cyclobutyl]amino]-2-oxoacetyl]-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound CNC(=O)C1(CC(F)(F)C1)NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n1C OUOGNXQMLHDWNG-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CLYKNQBARVDRHE-UHFFFAOYSA-N ethyl 1,4-dimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C1=CN(C)C=C1C CLYKNQBARVDRHE-UHFFFAOYSA-N 0.000 description 2
- PTLFTWNNUXCCLP-UHFFFAOYSA-N ethyl 4-fluoro-2-methyl-1H-pyrrole-3-carboxylate Chemical compound CCOC(=O)c1c(C)[nH]cc1F PTLFTWNNUXCCLP-UHFFFAOYSA-N 0.000 description 2
- ISHMBNDCGOGURC-UHFFFAOYSA-N ethyl 5-(2-ethoxy-2-oxoacetyl)-1,2,4-trimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1c(C)c(C(=O)OCC)c(C)n1C ISHMBNDCGOGURC-UHFFFAOYSA-N 0.000 description 2
- TWOLSUWIDGIAAP-UHFFFAOYSA-N ethyl 5-(2-ethoxy-2-oxoacetyl)-1,4-dimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1c(C)c(cn1C)C(=O)OCC TWOLSUWIDGIAAP-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- KIHMDSQRFOJJSX-UHFFFAOYSA-N methyl 5-(2-ethoxy-2-oxoacetyl)-1,4-dimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1c(C)c(cn1C)C(=O)OC KIHMDSQRFOJJSX-UHFFFAOYSA-N 0.000 description 2
- GWGOZTIQLFUELO-UHFFFAOYSA-N methyl 5-(2-ethoxy-2-oxoacetyl)-1-methylpyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1cc(cn1C)C(=O)OC GWGOZTIQLFUELO-UHFFFAOYSA-N 0.000 description 2
- YBDFYFNLJGLYIV-UHFFFAOYSA-N methyl 5-[2-(tert-butylamino)-2-oxoacetyl]-1-methylpyrrole-3-carboxylate Chemical compound COC(=O)c1cc(C(=O)C(=O)NC(C)(C)C)n(C)c1 YBDFYFNLJGLYIV-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YNGVTASLUMUBOY-UHFFFAOYSA-N tert-butyl N-[3,3-difluoro-1-(methylcarbamoyl)cyclobutyl]carbamate Chemical compound FC1(CC(C1)(C(NC)=O)NC(OC(C)(C)C)=O)F YNGVTASLUMUBOY-UHFFFAOYSA-N 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- OBMKZINZPBARIK-UHFFFAOYSA-N (1-aminocyclopropyl)methanol Chemical compound OCC1(N)CC1 OBMKZINZPBARIK-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- VLVCERQEOKPRTG-HSHFZTNMSA-N (2r)-1,1,1-trifluoropropan-2-amine;hydrochloride Chemical compound Cl.C[C@@H](N)C(F)(F)F VLVCERQEOKPRTG-HSHFZTNMSA-N 0.000 description 1
- BMCBDSKJVXYMJF-UHFFFAOYSA-N (3-aminocyclobutyl)methanol Chemical compound NC1CC(CO)C1 BMCBDSKJVXYMJF-UHFFFAOYSA-N 0.000 description 1
- HBGXGFLFLLDTML-UHFFFAOYSA-N (3-aminooxetan-3-yl)methanol Chemical compound OCC1(N)COC1 HBGXGFLFLLDTML-UHFFFAOYSA-N 0.000 description 1
- MIPHRQMEIYLZFZ-SCSAIBSYSA-N (3r)-oxolan-3-amine Chemical group N[C@@H]1CCOC1 MIPHRQMEIYLZFZ-SCSAIBSYSA-N 0.000 description 1
- MIPHRQMEIYLZFZ-BYPYZUCNSA-N (3s)-oxolan-3-amine Chemical group N[C@H]1CCOC1 MIPHRQMEIYLZFZ-BYPYZUCNSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KDWQLICBSFIDRM-UHFFFAOYSA-N 1,1,1-trifluoropropane Chemical compound CCC(F)(F)F KDWQLICBSFIDRM-UHFFFAOYSA-N 0.000 description 1
- QXZFWGCKCFGDLK-UHFFFAOYSA-N 1,2,4-trimethyl-N-(3,4,5-trifluorophenyl)pyrrole-3-carboxamide Chemical compound Cc1cn(C)c(C)c1C(=O)Nc1cc(F)c(F)c(F)c1 QXZFWGCKCFGDLK-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- XNJJEIXEPFPPSE-UHFFFAOYSA-N 1-benzylsulfonyl-4-fluoro-2-methyl-2,5-dihydropyrrole-3-carboxylic acid Chemical compound CC1N(CC(F)=C1C(O)=O)S(=O)(=O)Cc1ccccc1 XNJJEIXEPFPPSE-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 1
- SZNQBPDRIVNYMJ-UHFFFAOYSA-N 2,4-dibromo-5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1-methylpyrrole-3-carboxamide Chemical compound Cn1c(Br)c(C(=O)Nc2ccc(F)c(c2)C#N)c(Br)c1C(=O)C(=O)NC(C)(C)C SZNQBPDRIVNYMJ-UHFFFAOYSA-N 0.000 description 1
- XBPJVSRTTKVMEN-UHFFFAOYSA-M 2,4-dimethyl-1h-pyrrole-3-carboxylate Chemical compound CC1=CNC(C)=C1C([O-])=O XBPJVSRTTKVMEN-UHFFFAOYSA-M 0.000 description 1
- NSYGOGKILLUKFR-UHFFFAOYSA-N 2-(4-ethoxycarbonyl-1,5-dimethylpyrrol-2-yl)-2-oxoacetic acid Chemical compound CCOC(=O)c1cc(C(=O)C(O)=O)n(C)c1C NSYGOGKILLUKFR-UHFFFAOYSA-N 0.000 description 1
- HGZDPBICZXDZKJ-UHFFFAOYSA-N 2-(4-ethoxycarbonyl-3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid Chemical compound CCOC(=O)C1=C(C)NC(C(=O)C(O)=O)=C1C HGZDPBICZXDZKJ-UHFFFAOYSA-N 0.000 description 1
- KCFMXTUSVUTIDP-UHFFFAOYSA-N 2-(4-methoxycarbonyl-1,3-dimethylpyrrol-2-yl)-2-oxoacetic acid Chemical compound COC(=O)C=1C(=C(N(C=1)C)C(C(=O)O)=O)C KCFMXTUSVUTIDP-UHFFFAOYSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- MFKKXLXFRKFOAH-UHFFFAOYSA-N 2-[4-ethoxycarbonyl-5-(methoxymethyl)-1-methylpyrrol-2-yl]-2-oxoacetic acid Chemical compound CCOC(=O)c1cc(C(=O)C(O)=O)n(C)c1COC MFKKXLXFRKFOAH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- VFQDFQDXMNVDPW-UHFFFAOYSA-N 2-amino-5-fluorobenzonitrile Chemical compound NC1=CC=C(F)C=C1C#N VFQDFQDXMNVDPW-UHFFFAOYSA-N 0.000 description 1
- VMPHGCPFQRXBOW-UHFFFAOYSA-N 2-bromo-5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1,4-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(Br)n(C)c1C(=O)C(=O)NC(C)(C)C VMPHGCPFQRXBOW-UHFFFAOYSA-N 0.000 description 1
- RMYKPQGWNIHXGQ-UHFFFAOYSA-N 2-bromo-5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1-methylpyrrole-3-carboxamide Chemical compound Cn1c(Br)c(cc1C(=O)C(=O)NC(C)(C)C)C(=O)Nc1ccc(F)c(c1)C#N RMYKPQGWNIHXGQ-UHFFFAOYSA-N 0.000 description 1
- HUOCRTQRDGWYTA-RXMQYKEDSA-N 2-chloro-1,4-dimethyl-5-[2-oxo-2-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxylic acid Chemical compound ClC=1N(C(=C(C=1C(=O)O)C)C(C(N[C@@H](C(F)(F)F)C)=O)=O)C HUOCRTQRDGWYTA-RXMQYKEDSA-N 0.000 description 1
- MANJIGKYCYWWBD-UHFFFAOYSA-N 2-chloro-2-oxoacetic acid Chemical compound OC(=O)C(Cl)=O MANJIGKYCYWWBD-UHFFFAOYSA-N 0.000 description 1
- AETLNOYZBHXWLS-UHFFFAOYSA-N 2-chloro-N-(3-cyano-4-fluorophenyl)-1,4-dimethyl-5-[2-[(3-methyloxetan-3-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(Cl)n(C)c1C(=O)C(=O)NC1(C)COC1 AETLNOYZBHXWLS-UHFFFAOYSA-N 0.000 description 1
- OFMXPBJLUHAEDO-UHFFFAOYSA-N 2-chloro-N-(3-cyano-4-fluorophenyl)-5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-2-oxoacetyl]-1,4-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(Cl)n(C)c1C(=O)C(=O)NC(C)(C)CO OFMXPBJLUHAEDO-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XLIWIIMJAODJPZ-UHFFFAOYSA-N 3,3-dimethylheptan-1-amine Chemical compound CCCCC(C)(C)CCN XLIWIIMJAODJPZ-UHFFFAOYSA-N 0.000 description 1
- SZRDJHHKIJHJHQ-UHFFFAOYSA-N 3,4,5-trifluoroaniline Chemical compound NC1=CC(F)=C(F)C(F)=C1 SZRDJHHKIJHJHQ-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical group NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- NJCYYGYIMLSZJS-UHFFFAOYSA-N 3-amino-3-methylcyclobutan-1-ol Chemical compound CC1(N)CC(O)C1 NJCYYGYIMLSZJS-UHFFFAOYSA-N 0.000 description 1
- RTAWFZMTTJCICN-UHFFFAOYSA-N 3-amino-3-methylcyclobutan-1-ol;hydrochloride Chemical compound Cl.CC1(N)CC(O)C1 RTAWFZMTTJCICN-UHFFFAOYSA-N 0.000 description 1
- FJHVWOFTAJCONF-UHFFFAOYSA-N 3-amino-5-fluorobenzonitrile Chemical compound NC1=CC(F)=CC(C#N)=C1 FJHVWOFTAJCONF-UHFFFAOYSA-N 0.000 description 1
- XUMSHCRPQCZRGX-UHFFFAOYSA-N 3-aminocyclobutan-1-ol;hydrochloride Chemical compound Cl.NC1CC(O)C1 XUMSHCRPQCZRGX-UHFFFAOYSA-N 0.000 description 1
- PMKPNGBRDFIFNX-UHFFFAOYSA-N 3-methyl-1,1-dioxothietan-3-amine Chemical compound CC1(N)CS(=O)(=O)C1 PMKPNGBRDFIFNX-UHFFFAOYSA-N 0.000 description 1
- NQVWMPOQWBDSAI-UHFFFAOYSA-N 3-methyloxetan-3-amine Chemical compound CC1(N)COC1 NQVWMPOQWBDSAI-UHFFFAOYSA-N 0.000 description 1
- VSAPWIUQDZKEBG-UHFFFAOYSA-N 3-methyloxolan-3-amine Chemical compound CC1(N)CCOC1 VSAPWIUQDZKEBG-UHFFFAOYSA-N 0.000 description 1
- BLBDTBCGPHPIJK-UHFFFAOYSA-N 4-Amino-2-chloropyridine Chemical compound NC1=CC=NC(Cl)=C1 BLBDTBCGPHPIJK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KTPAKCIGNJGDCX-UHFFFAOYSA-N 4-fluoro-1,2-dimethylpyrrole-3-carboxylic acid Chemical compound CC1=C(C(O)=O)C(F)=CN1C KTPAKCIGNJGDCX-UHFFFAOYSA-N 0.000 description 1
- NYMDPDNETOLVBS-UHFFFAOYSA-N 4-fluoro-3-methylaniline Chemical group CC1=CC(N)=CC=C1F NYMDPDNETOLVBS-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical group NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- QNDFYLBDUWCFJO-UHFFFAOYSA-N 4-fluorobenzene-1,3-diamine Chemical group NC1=CC=C(F)C(N)=C1 QNDFYLBDUWCFJO-UHFFFAOYSA-N 0.000 description 1
- OVMVMMNHNMZUAS-UHFFFAOYSA-N 4-methyl-1,3-dithiolane-2-thione Chemical group CC1CSC(=S)S1 OVMVMMNHNMZUAS-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- QEFSFBDVNNYDRW-UHFFFAOYSA-N 5-[2-(1-bicyclo[1.1.1]pentanylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1,2,4-trimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC12CC(C1)C2 QEFSFBDVNNYDRW-UHFFFAOYSA-N 0.000 description 1
- JZRHHJBQTAVSDZ-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-1,2,4-trimethylpyrrole-3-carboxylic acid Chemical compound C(C)(C)(C)NC(C(=O)C1=C(C(=C(N1C)C)C(=O)O)C)=O JZRHHJBQTAVSDZ-UHFFFAOYSA-N 0.000 description 1
- CILCGFXTQJWBCK-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cc(C(=O)C(=O)NC(C)(C)C)n1C)C(=O)Nc1ccc(F)c(c1)C#N CILCGFXTQJWBCK-UHFFFAOYSA-N 0.000 description 1
- YDHZUMVWTDGIDF-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1,4-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cn(C)c1C(=O)C(=O)NC(C)(C)C)C(=O)Nc1ccc(F)c(c1)C#N YDHZUMVWTDGIDF-UHFFFAOYSA-N 0.000 description 1
- SDGMGYZHOYITDI-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-1-methylpyrrole-3-carboxamide Chemical compound Cn1cc(cc1C(=O)C(=O)NC(C)(C)C)C(=O)Nc1ccc(F)c(c1)C#N SDGMGYZHOYITDI-UHFFFAOYSA-N 0.000 description 1
- UOLORMZIKHQTDQ-UHFFFAOYSA-N 5-[2-(tert-butylamino)-2-oxoacetyl]-N-(3-cyano-4-fluorophenyl)-2-fluoro-1-methylpyrrole-3-carboxamide Chemical compound Cn1c(F)c(cc1C(=O)C(=O)NC(C)(C)C)C(=O)Nc1ccc(F)c(c1)C#N UOLORMZIKHQTDQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OFTNDPGPQRJURF-AKAXFMLLSA-N C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@@H](C1)CO)=O)C)C Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(=O)N[C@@H]1C[C@@H](C1)CO)=O)C)C OFTNDPGPQRJURF-AKAXFMLLSA-N 0.000 description 1
- LJFHZQIQJNNPDF-UHFFFAOYSA-N C(C1=CC=CC=C1)S(=O)(=O)NOC(C)C(C(=O)OCC)=C=C Chemical compound C(C1=CC=CC=C1)S(=O)(=O)NOC(C)C(C(=O)OCC)=C=C LJFHZQIQJNNPDF-UHFFFAOYSA-N 0.000 description 1
- FSHGTEQKAHRVEM-UHFFFAOYSA-N CC(C(F)(F)F)NC(C(C)=O)=O Chemical compound CC(C(F)(F)F)NC(C(C)=O)=O FSHGTEQKAHRVEM-UHFFFAOYSA-N 0.000 description 1
- FOBMPKFQQKZZOS-UHFFFAOYSA-N CC(C(NC1(CO)COC1)=O)=O Chemical compound CC(C(NC1(CO)COC1)=O)=O FOBMPKFQQKZZOS-UHFFFAOYSA-N 0.000 description 1
- LINSHEGFJMVFOS-UHFFFAOYSA-N CC(C(NC1CCN(C)CC1)=O)=O Chemical compound CC(C(NC1CCN(C)CC1)=O)=O LINSHEGFJMVFOS-UHFFFAOYSA-N 0.000 description 1
- KJTIBPZHIHFMEI-UHFFFAOYSA-N CC(C(NCC#C)=O)=O Chemical compound CC(C(NCC#C)=O)=O KJTIBPZHIHFMEI-UHFFFAOYSA-N 0.000 description 1
- SLOBJYUYNRLDBF-UHFFFAOYSA-N CC(C)(C(OC)=O)NC(C(C)=O)=O Chemical compound CC(C)(C(OC)=O)NC(C(C)=O)=O SLOBJYUYNRLDBF-UHFFFAOYSA-N 0.000 description 1
- SEIHFWJBYXWSPT-UHFFFAOYSA-N CC(C)(C(OC)=O)NC(C(c1c(C)c(C(Nc(cc2)cc(C#N)c2F)=O)c(C)[n]1C)O)=O Chemical compound CC(C)(C(OC)=O)NC(C(c1c(C)c(C(Nc(cc2)cc(C#N)c2F)=O)c(C)[n]1C)O)=O SEIHFWJBYXWSPT-UHFFFAOYSA-N 0.000 description 1
- NXOFYGCPICKXJV-UHFFFAOYSA-N CC(C)(C)NC(C(C)=O)=O Chemical compound CC(C)(C)NC(C(C)=O)=O NXOFYGCPICKXJV-UHFFFAOYSA-N 0.000 description 1
- OATGBAZPMTZOAH-UHFFFAOYSA-N CC(C)(CO)NC(C=O)=O Chemical compound CC(C)(CO)NC(C=O)=O OATGBAZPMTZOAH-UHFFFAOYSA-N 0.000 description 1
- QNWDWCWGUTWDNK-UHFFFAOYSA-N CC(CC(N1CCN(C)CC1)=O)=O Chemical compound CC(CC(N1CCN(C)CC1)=O)=O QNWDWCWGUTWDNK-UHFFFAOYSA-N 0.000 description 1
- BGYDXCOLCGBZKC-UHFFFAOYSA-N CC(CC(NC1COC1)=O)=O Chemical compound CC(CC(NC1COC1)=O)=O BGYDXCOLCGBZKC-UHFFFAOYSA-N 0.000 description 1
- BWRXZEMBWKNDQS-UHFFFAOYSA-N CC1(CCOCC1)NC(C(C)=O)=O Chemical compound CC1(CCOCC1)NC(C(C)=O)=O BWRXZEMBWKNDQS-UHFFFAOYSA-N 0.000 description 1
- QKNAQCRGBJVBCF-UHFFFAOYSA-N CC1(COCC1)NC(C(C)=O)=O Chemical compound CC1(COCC1)NC(C(C)=O)=O QKNAQCRGBJVBCF-UHFFFAOYSA-N 0.000 description 1
- BDVLECDDIGKIAB-UHFFFAOYSA-N CC1=C(N(C(=C1C(=O)N)C)C)C(=O)C(=O)NC(C)C(F)(F)F Chemical compound CC1=C(N(C(=C1C(=O)N)C)C)C(=O)C(=O)NC(C)C(F)(F)F BDVLECDDIGKIAB-UHFFFAOYSA-N 0.000 description 1
- PTFMUNZNDLDORF-UHFFFAOYSA-N CCCS(CCNC(C(C)=O)=O)(=O)=O Chemical compound CCCS(CCNC(C(C)=O)=O)(=O)=O PTFMUNZNDLDORF-UHFFFAOYSA-N 0.000 description 1
- FARNJIRGTKXLLX-UHFFFAOYSA-N CCOC(=O)C(=C=C)C(C)NS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound CCOC(=O)C(=C=C)C(C)NS(=O)(=O)C1=CC=C(C)C=C1 FARNJIRGTKXLLX-UHFFFAOYSA-N 0.000 description 1
- LPCLSUBMHORWEV-UHFFFAOYSA-N CCOC(C(c1cc(C(Nc(cc2C#N)ccc2F)=O)c[n]1C)=O)=O Chemical compound CCOC(C(c1cc(C(Nc(cc2C#N)ccc2F)=O)c[n]1C)=O)=O LPCLSUBMHORWEV-UHFFFAOYSA-N 0.000 description 1
- ZMZCGGGBORROMW-UHFFFAOYSA-N CCOC(c1c(C)[n](C)c(C(C(NC(C)(C)C)=O)=O)c1C)=O Chemical compound CCOC(c1c(C)[n](C)c(C(C(NC(C)(C)C)=O)=O)c1C)=O ZMZCGGGBORROMW-UHFFFAOYSA-N 0.000 description 1
- YSFJFNNQZXHCSP-UHFFFAOYSA-N CNC(=O)C1(N)CC(F)(F)C1 Chemical class CNC(=O)C1(N)CC(F)(F)C1 YSFJFNNQZXHCSP-UHFFFAOYSA-N 0.000 description 1
- 101150051438 CYP gene Proteins 0.000 description 1
- LCPIHRAVZLSVJX-LBPRGKRZSA-N C[C@@H](C(F)(F)F)NC(C(c1c(C)c(C(Nc(cc2)cc(C)c2F)=O)c(C)[n]1C)=O)=O Chemical compound C[C@@H](C(F)(F)F)NC(C(c1c(C)c(C(Nc(cc2)cc(C)c2F)=O)c(C)[n]1C)=O)=O LCPIHRAVZLSVJX-LBPRGKRZSA-N 0.000 description 1
- YPKHAPHTKGOPJR-UHFFFAOYSA-N C[n]1c(C(C(NC2(COC2)C(F)(F)F)=O)=O)cc(C(Nc(cc2C#N)ccc2F)=O)c1 Chemical compound C[n]1c(C(C(NC2(COC2)C(F)(F)F)=O)=O)cc(C(Nc(cc2C#N)ccc2F)=O)c1 YPKHAPHTKGOPJR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- IKGXTSGHHVMGHO-UHFFFAOYSA-N Cc1c(C(C(N(C)C(C2)(CC2(F)F)C(N(C)C)=O)=O)=O)[n](C)c(C)c1C(Nc(cc1)cc(C#N)c1F)=O Chemical compound Cc1c(C(C(N(C)C(C2)(CC2(F)F)C(N(C)C)=O)=O)=O)[n](C)c(C)c1C(Nc(cc1)cc(C#N)c1F)=O IKGXTSGHHVMGHO-UHFFFAOYSA-N 0.000 description 1
- VKSOFHRFVQGJTC-UHFFFAOYSA-N Cc1c(C(C(NC2(COC2)C(F)(F)F)=O)=O)[n](C)c(Cl)c1C(Nc(cc1C#N)ccc1F)=O Chemical compound Cc1c(C(C(NC2(COC2)C(F)(F)F)=O)=O)[n](C)c(Cl)c1C(Nc(cc1C#N)ccc1F)=O VKSOFHRFVQGJTC-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- INWWBKYVUDKMQF-JTQLQIEISA-N N-(2-chloropyridin-4-yl)-1,2,4-trimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxamide Chemical compound C[C@H](NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccnc(Cl)c2)c(C)n1C)C(F)(F)F INWWBKYVUDKMQF-JTQLQIEISA-N 0.000 description 1
- KNUYOTJIABUKIV-NSHDSACASA-N N-(3-acetamido-4-fluorophenyl)-1,2,4-trimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxamide Chemical compound C[C@H](NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(NC(C)=O)c2)c(C)n1C)C(F)(F)F KNUYOTJIABUKIV-NSHDSACASA-N 0.000 description 1
- IYSXPNCEQDVGIV-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-1,2,4-trimethyl-5-[2-[(4-methyloxan-4-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(Cl)c2)c(C)n(C)c1C(=O)C(=O)NC1(C)CCOCC1 IYSXPNCEQDVGIV-UHFFFAOYSA-N 0.000 description 1
- KXMBVHULTGNXAO-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-(4-methylpiperazin-1-yl)-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound CN1CCN(CC1)C(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n1C KXMBVHULTGNXAO-UHFFFAOYSA-N 0.000 description 1
- JJZVLYDJZIEPAQ-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-[(1-methylpiperidin-4-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound CN1CCC(CC1)NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n1C JJZVLYDJZIEPAQ-UHFFFAOYSA-N 0.000 description 1
- WSQMOBYMTWGXEA-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-[2-[(4-methyloxan-4-yl)amino]-2-oxoacetyl]pyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(C)n(C)c1C(=O)C(=O)NC1(C)CCOCC1 WSQMOBYMTWGXEA-UHFFFAOYSA-N 0.000 description 1
- ALPXGYHAXUPRQL-HPRDVNIFSA-N N-(3-cyano-4-fluorophenyl)-2,4-dimethyl-1-(trideuteriomethyl)pyrrole-3-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C=C1C)C([2H])([2H])[2H])C ALPXGYHAXUPRQL-HPRDVNIFSA-N 0.000 description 1
- ZEKBUUAAJKFKCP-ZTJILHFHSA-N N-(3-cyano-4-fluorophenyl)-2,4-dimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]-1-(trideuteriomethyl)pyrrole-3-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)C1=C(N(C(=C1C)C(C(N[C@H](C(F)(F)F)C)=O)=O)C([2H])([2H])[2H])C ZEKBUUAAJKFKCP-ZTJILHFHSA-N 0.000 description 1
- UFYPMGXYYFELBB-VIFPVBQESA-N N-(3-cyano-4-fluorophenyl)-2-fluoro-1,4-dimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxamide Chemical compound C[C@H](NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(c2)C#N)c(F)n1C)C(F)(F)F UFYPMGXYYFELBB-VIFPVBQESA-N 0.000 description 1
- AXIJUSMIEYNNPC-UHFFFAOYSA-N N-(3-cyano-4-fluorophenyl)-4-fluoro-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(C(=O)Nc2ccc(F)c(c2)C#N)c(F)cn1C AXIJUSMIEYNNPC-UHFFFAOYSA-N 0.000 description 1
- QOEWWWOGCHPOOR-NSHDSACASA-N N-(4-fluorophenyl)-1,2,4-trimethyl-5-[2-oxo-2-[[(2S)-1,1,1-trifluoropropan-2-yl]amino]acetyl]pyrrole-3-carboxamide Chemical compound C[C@H](NC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)cc2)c(C)n1C)C(F)(F)F QOEWWWOGCHPOOR-NSHDSACASA-N 0.000 description 1
- RQGIAUXGSWYJGE-UHFFFAOYSA-N NC1(COC1)C(F)(F)F Chemical compound NC1(COC1)C(F)(F)F RQGIAUXGSWYJGE-UHFFFAOYSA-N 0.000 description 1
- RTYVPQBCRDMGFE-UHFFFAOYSA-N O=CC(NC1(C2)CC2C1)=O Chemical compound O=CC(NC1(C2)CC2C1)=O RTYVPQBCRDMGFE-UHFFFAOYSA-N 0.000 description 1
- GTCMENLMGYWPSJ-UHFFFAOYSA-N O=CC(NC1COCC1)=O Chemical compound O=CC(NC1COCC1)=O GTCMENLMGYWPSJ-UHFFFAOYSA-N 0.000 description 1
- NUKWOAKUNGCPAX-UHFFFAOYSA-N OCC(C1)CC1NC(C=O)=O Chemical compound OCC(C1)CC1NC(C=O)=O NUKWOAKUNGCPAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- GDHXZQNQHWTMCM-UHFFFAOYSA-N ethyl 1,2-dimethylpyrrole-3-carboxylate Chemical group CCOC(=O)C=1C=CN(C)C=1C GDHXZQNQHWTMCM-UHFFFAOYSA-N 0.000 description 1
- KNDQVVRIAMEXIV-UHFFFAOYSA-N ethyl 1-benzylsulfonyl-4-fluoro-2-methyl-2,5-dihydropyrrole-3-carboxylate Chemical compound FC1=C(C(N(C1)S(=O)(=O)CC1=CC=CC=C1)C)C(=O)OCC KNDQVVRIAMEXIV-UHFFFAOYSA-N 0.000 description 1
- ICJYWDHNTMJKFP-UHFFFAOYSA-N ethyl 1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=CNC=1 ICJYWDHNTMJKFP-UHFFFAOYSA-N 0.000 description 1
- PUJICPRRQXQDOM-GKOSEXJESA-N ethyl 2,4-dimethyl-1-(trideuteriomethyl)pyrrole-3-carboxylate Chemical compound CC=1N(C=C(C=1C(=O)OCC)C)C([2H])([2H])[2H] PUJICPRRQXQDOM-GKOSEXJESA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- DJDPDVJJTIGJTE-UHFFFAOYSA-N ethyl 2-methyl-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=CNC=1C DJDPDVJJTIGJTE-UHFFFAOYSA-N 0.000 description 1
- IVDDYDPBNCATFP-UHFFFAOYSA-N ethyl 4-fluoro-1,2-dimethylpyrrole-3-carboxylate Chemical compound CCOC(=O)c1c(F)cn(C)c1C IVDDYDPBNCATFP-UHFFFAOYSA-N 0.000 description 1
- IINXAZLWINRVFV-UHFFFAOYSA-N ethyl 5-(2-ethoxy-2-oxoacetyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate Chemical compound CCOC(=O)C(=O)c1[nH]c(C)c(C(=O)OCC)c1C IINXAZLWINRVFV-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethylcyclohexane Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TUMYWMIKKQMMSS-UHFFFAOYSA-N methyl 1,4-dimethylpyrrole-3-carboxylate Chemical group COC(=O)C1=CN(C)C=C1C TUMYWMIKKQMMSS-UHFFFAOYSA-N 0.000 description 1
- WLBNVSIQCFHAQB-UHFFFAOYSA-N methyl 1h-pyrrole-3-carboxylate Chemical compound COC(=O)C=1C=CNC=1 WLBNVSIQCFHAQB-UHFFFAOYSA-N 0.000 description 1
- NVWZNEDLYYLQJC-UHFFFAOYSA-N methyl 2-amino-2-methylpropanoate;hydrochloride Chemical compound Cl.COC(=O)C(C)(C)N NVWZNEDLYYLQJC-UHFFFAOYSA-N 0.000 description 1
- OBRHFSNTJHVMMB-UHFFFAOYSA-N methyl 2-methyl-1h-pyrrole-3-carboxylate Chemical group COC(=O)C=1C=CNC=1C OBRHFSNTJHVMMB-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JUIXJPRSYHSLHK-UHFFFAOYSA-N n-methyloxetan-3-amine Chemical compound CNC1COC1 JUIXJPRSYHSLHK-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- ZGNYUQSBJCCWGF-UHFFFAOYSA-N oxetan-3-amine;hydrochloride Chemical compound Cl.NC1COC1 ZGNYUQSBJCCWGF-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- MIPHRQMEIYLZFZ-UHFFFAOYSA-N oxolan-3-amine Chemical compound NC1CCOC1 MIPHRQMEIYLZFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002105 relative biological effectiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KYDJQJAIHCVQPO-UHFFFAOYSA-N tert-butyl n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)OC(C)(C)C KYDJQJAIHCVQPO-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H]C([2H])[2H] VNWKTOKETHGBQD-FIBGUPNXSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present application relates to a compound of the formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, and a process for the preparation thereof , a pharmaceutical composition containing the same, and its use as a medicament for treating hepatitis B virus infection.
- chronic hepatitis B can only be controlled without treatment, and is currently limited to two types of agents (interferons and inhibitors of nucleoside analogs/viral polymerases).
- the lower cure rate of HBV is due in part to the presence and persistence of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes.
- Current treatment protocols are unable to remove cccDNA from the repository, and some new targets for HBV such as core inhibitors (such as viral capsid protein formation or assembly inhibitors and cccDNA inhibitors and interferon-stimulated gene activators) Etc.) is expected to bring hope to cure hepatitis B (Mayur Brahmania, et al. New therapeutic agents for chronic hepatitis B).
- the HBV capsid is assembled from the core protein.
- HBV reverse transcriptase and pgRNA need to be correctly encapsulated by the capsid protein. Therefore, blocking capsid protein assembly, or accelerating capsid protein degradation, blocks the assembly process of the capsid protein, thereby affecting viral replication.
- inhibitors of capsid protein assembly such as WO2014184350, WO2015011281, WO2017156255, etc., which disclose a series of related compounds. However, most of them are in the early stage of clinical research or the research has been terminated, and there is a need in the art for more alternative effective capsid protein assembly inhibitors for treating, ameliorating or preventing HBV infection.
- the present invention synthesizes a series of novel derivatives and studies the HBV protein assembly activity.
- the present application relates to compounds of formula I, stereoisomers, tautomers, geometric isomers, solvates, active metabolites, hydrates, prodrugs or pharmaceutically acceptable salts thereof,
- X and Y each independently represent CR 7, said R 7 are independently selected from hydrogen, C 3-4 cycloalkyl, -CN, fluoro, chloro, bromo or C 1-3 alkyl, said C 1-3 An alkyl group is optionally substituted with one or more groups selected from the group consisting of fluorine, chlorine, bromine, C 1-6 alkoxy, -OH, -NH 2 or -CN;
- Ring A is selected from phenyl or 5-10 membered heteroaryl
- R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, -CHF 2 , -CH 2 F, -CF 3 , -CN, C 1-3 alkyl, -NH 2 , C 3 a -4 cycloalkyl group, -NHR a or -NR b R c , wherein R a , R b , R c are each independently selected from -C(O)C 1-6 alkyl, C 1-6 alkyl, - S(O) 2 C 1-6 alkyl, 5-10 membered heteroaryl, C 6-10 aryl, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl;
- R 4 is selected from the group consisting of hydrogen, C 1-3 alkyl or C 3-4 cycloalkyl
- R 5 is selected from C 1 - 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, 3-7-membered cycloalkyl or 3-7-membered heterocycloalkyl, said C 1 - 6 alkyl
- a C 2 -6 alkenyl group, a C 2 -6 alkynyl group, a 3-7 membered cycloalkyl group or a 3-7 membered heterocycloalkyl group is optionally substituted by a halogen group, a 3-4 membered cycloalkyl group, 3-4 membered heterocycloalkyl, -OR 8 , oxo, -CN, -C(O)OR 8 , -SO 2 R 8 , -C(O)N(R 8 ) 2 or optionally Or a plurality of C 1-3 alkyl groups substituted with fluorine, -CN or -OH;
- R 8 is each independently selected from hydrogen or C 1-3 alkyl.
- above X and Y each independently represent CR 7 , said R 7 being independently selected from hydrogen, fluoro, chloro, bromo or C 1-3 alkyl, said C 1-3 alkyl optionally Substituted by one or more groups selected from fluoro or C 1-3 alkoxy; in some embodiments, said R 7 is independently selected from hydrogen, fluoro, chloro, bromo or optionally by one or a plurality of methoxy-substituted C 1-3 alkyl groups; in some embodiments, the R 7 is independently selected from hydrogen, fluoro, chloro, bromo, -CH 2 OCH 3 or methyl; in some embodiments And R 7 is independently selected from hydrogen, chlorine, bromine or methyl.
- X and Y each independently represent CR 7, said R 7 are independently selected from hydrogen, C3-4 cycloalkyl, -CN, fluorine, chlorine, bromine or optionally substituted with one or more Fluorine substituted C1-3 alkyl.
- the above-mentioned X and Y each independently represent CR 7, said R 7 are independently selected from hydrogen, fluorine, chlorine, bromine or optionally substituted with one or more fluorine of a C 1-3 alkoxy
- the R 7 is independently selected from hydrogen, fluoro, chloro, bromo or C 1-3 alkyl; in other embodiments, the R 7 is independently selected from hydrogen, fluoro. , chlorine, bromine or methyl.
- the above ring A is selected from the group consisting of phenyl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 9-membered heteroaryl or 10-membered heteroaryl; In some embodiments, Ring A is selected from phenyl or 6-membered heteroaryl; in some embodiments, Ring A is selected from phenyl or pyridyl. In some embodiments, the heteroaryl group present in the definition of Ring A above contains 1 or 2 N atoms.
- Ring A is selected from the group consisting of phenyl.
- R a is selected from -C (O) C 1-3 alkyl, C 1-3 alkyl, -S (O) 2 C 1-3 alkyl, 5-6 membered heteroaryl, C 6-10 aryl, C 3-6 cycloalkyl, or 3-6 membered heterocycloalkyl; in some embodiments, R a is selected from -C (O) C 1-3 alkyl, C 1- 3 alkyl, or -S (O) 2 C 1-3 alkyl; in some embodiments, R a is selected from -C (O) CH 3, or -S (O) 2 CH 3.
- R b , R c are each independently selected from -C(O)C 1-3 alkyl, C 1-3 alkyl, -S(O) 2 C 1-3 alkyl, 5- a 6-membered heteroaryl, C 6-10 aryl, C 3-6 cycloalkyl, or 3-6 membered heterocycloalkyl; in some embodiments, R b , R c are each independently selected from -C ( O) C 1-3 alkyl, C 1-3 alkyl, or -S(O) 2 C 1-3 alkyl.
- R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CHF 2 , —CH 2 F, —CF 3 , —CN, C 1-3 alkyl. , -NH 2 , or C 3-4 cycloalkyl.
- R 1 above is selected from hydrogen, fluoro, chloro, -CHF 2 , -CN, -CF 3 or methyl; in some embodiments, R 1 above is selected from hydrogen or fluoro.
- the above R 2 is selected from hydrogen, fluorine, chlorine or bromine; in some embodiments, the above R 2 is selected from hydrogen or fluorine.
- R 3 above is selected from the group consisting of hydrogen, fluoro, chloro, -CHF 2 , -CN, -CF 3 , methyl, -NH 2 or -NHR a ; in some embodiments, R 3 above is selected from Hydrogen, fluorine, chlorine, -CHF 2 , -CN, -CF 3 , methyl, -NH 2 , -NHC(O)CH 3 , or -NHS(O) 2 CH 3 ; in some embodiments, R above 3 is selected from the group consisting of hydrogen, fluorine, chlorine, -CHF 2 , -CN, -CF 3 , methyl or -NH 2 ; in some embodiments, the above R 3 is selected from the group consisting of hydrogen, fluorine, chlorine, -CN, methyl or -NH 2 .
- R 1 is selected from hydrogen, fluoro, chloro, -CHF 2 , -CN, -CF 3 or methyl, and at least one of R 1 and R 3 is fluoro or hydrogen.
- one of R 1 and R 3 is selected from hydrogen or fluorine, and the other is selected from the group consisting of hydrogen, fluorine, chlorine, —CHF 2 , —CN, —CF 3 , methyl or —NH 2 .
- R 2 is selected from the group consisting of fluorine, chlorine or bromine, one of R 1 and R 3 is hydrogen, and the other is selected from the group consisting of hydrogen, fluorine, chlorine, —CHF 2 , —CN, —CF 3 or methyl;
- R 2 above is selected from fluoro, R 1 and R 3 are each hydrogen, and the other is selected from fluoro, chloro or —CN; in some embodiments, R 2 is selected from fluoro and R 1 is hydrogen.
- R 3 is -CN or chlorine.
- R 2 above is selected from fluoro, R 1 is hydrogen, and R 3 is —CN.
- one of R 1 and R 3 is hydrogen and the other is selected from the group consisting of fluorine, chlorine, —CHF 2 , —CN, —CF 3 or methyl.
- X and Y each independently represent CR 7, said R 7 are independently selected from hydrogen, C 3-4 cycloalkyl, -CN, fluorine, chlorine, bromine or optionally substituted with one or a plurality of fluorine-substituted C 1-3 alkyl groups; R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, -CHF 2 , -CH 2 F, -CF 3 , -CN, C 1-3 alkyl or C 3-4 cycloalkyl.
- R 4 above is selected from hydrogen or C 1-3 alkyl; in some embodiments, R 4 above is methyl or hydrogen.
- R 4 above is methyl
- the above R 5 is selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-6 membered cycloalkyl or 4-6 membered heterocycloalkyl,
- the C 1-4 alkyl group, the C 2-4 alkenyl group, the C 2-4 alkynyl group, the 3-6 membered cycloalkyl group or the 4-6 membered heterocycloalkyl group are optionally substituted by the following groups: halogen, 3 -4 membered cycloalkyl, 3-4 membered heterocycloalkyl, -OR 8 , oxo, -CN, -C(O)OR 8 , -SO 2 R 8 , -C(O)N(R 8 ) 2 or a C 1-3 alkyl group optionally substituted by one or more fluorine, -CN or -OH; in some embodiments, the above R 5 is selected from C 1-4 alkyl, C 2-4 alkeny
- R 5 is selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-6 membered cycloalkyl or 4-6 membered heterocycloalkyl
- the C 1-4 alkyl group, C 2-4 alkenyl group, C 2-4 alkynyl group, 3-6 membered cycloalkyl group or 4-6 membered heterocycloalkyl group is optionally substituted with the following groups: halogen, -OH, -CN, -C(O)OR 8 , -C(O)N(R 8 ) 2 or a C 1-3 alkyl group optionally substituted by one or more fluorine or OH; in other embodiments
- R 5 is selected from C 1-4 alkyl, C 2-4 alkynyl, 3-6 membered cycloalkyl or 4-6 membered heterocycloalkyl, said C 1-4 alkyl, C 2 a -4 alkynyl
- the above R 5 is selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 4-6 membered cycloalkyl or 4-6 membered heterocycloalkyl.
- the C 1-4 alkyl group, C 2-4 alkenyl group, C 2-4 alkynyl group, 4-6 membered cycloalkyl group or 4-6 membered heterocycloalkyl group is optionally substituted by the following group: halogen 3-4 membered cycloalkyl, 3-4 membered heterocycloalkyl, -OR 8 , oxo, -CN, -C(O)OR 8 , -SO 2 R 8 , -C(O)N(R 8) 2 or optionally substituted with one or more fluorine, -CN or -OH, C 1-3 alkyl, said R 8 are each independently selected from hydrogen or C 1-3 alkyl; in yet a further In an embodiment, the above R 5 is selected from hydrogen
- the heterocycloalkyl group occurring in the definition of R 5 above contains 1 or 2 heteroatoms selected from N, O or S.
- each R 8 is independently selected from hydrogen or methyl.
- the structural unit Selected from In some embodiments, the structural unit Selected from
- the structural unit Selected from In some embodiments, the structural unit Selected from
- the structural unit Selected from In some embodiments, the structural unit Selected from
- the structural unit Selected from In other embodiments, the structural unit Selected from
- the structural unit Selected from In some embodiments, the structural unit Selected from
- the structural unit Selected from In other specific embodiments, the structural unit Selected from
- a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, of the present application is selected a compound of Formula II, Formula III or Formula IV, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof,
- R 1 , R 2 , R 3 , R 4 , R 5 , X, Y are as defined above;
- R 1 , R 2 , R 3 , X, Y are as defined above; structural units Selected from
- a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, of the present application is selected a compound of the formula II, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof,
- R 1 , R 2 , R 3 , R 4 , R 5 , X, Y are as defined above;
- R 1 , R 2 , R 3 structural unit and The definition is as shown above.
- a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, of the present application is selected a compound of formula III, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof,
- R 1 , R 2 , R 3 , R 4 , R 5 , X, Y are as defined above;
- R 1 , R 2 , R 3 structural unit and The definition is as shown above.
- a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, of the present application is selected From a compound of formula IV, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof,
- R 2 , R 3 , R 5 , X, Y are as defined above;
- R 2 , R 3 , X, Y structural unit
- the definition is as shown above.
- a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof, of the present application is selected From the following compounds, their stereoisomers, tautomers, geometric isomers, solvates, active metabolites, hydrates, prodrugs or pharmaceutically acceptable salts:
- the application provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, of the present application.
- the pharmaceutical compositions of the present application also include pharmaceutically acceptable excipients.
- the present application provides a method of treating a disease that benefits from inhibition of capsid protein assembly, comprising administering to a mammal in need of such treatment, preferably a human, a therapeutically effective amount of a compound of formula I above.
- a mammal in need of such treatment, preferably a human, a therapeutically effective amount of a compound of formula I above.
- An acceptable salt or a pharmaceutical composition thereof is an acceptable salt or a pharmaceutical composition thereof.
- the present application provides the use of a compound of formula I above, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the manufacture of a medicament for the prophylaxis or treatment of a disease which would benefit from inhibition of capsid protein assembly.
- the present application provides the use of a compound of formula I above, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for preventing or treating a disease which benefits from inhibition of capsid protein assembly.
- the present application provides a compound of the above formula I, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for preventing or treating a disease which benefits from inhibition of capsid protein assembly.
- the application provides a pharmaceutical composition comprising a compound of formula I, stereoisomers, tautomers, geometric isomers, solvates, active metabolites, hydrates, prodrugs thereof, of the present application. Or a pharmaceutically acceptable salt.
- the pharmaceutical compositions of the present application further comprise a pharmaceutically acceptable excipient.
- the present application provides a method of inhibiting capsid protein assembly comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, a stereoisomer, a tautomer thereof, a geometrical difference of the present application. A conformation, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt or pharmaceutical composition thereof.
- the individual is a mammal; in some embodiments, the individual is a human.
- the present application provides a method of preventing or treating a disease that benefits from inhibition of capsid protein assembly, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, a stereoisomer thereof, and a tautomer thereof of the present application.
- the individual is a mammal; in some embodiments, the individual is a human.
- the invention provides a compound of formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable thereof, of the present application.
- a salt or a pharmaceutical composition thereof for inhibiting capsid protein assembly.
- the invention provides a compound of formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable thereof, of the present application.
- a salt or a pharmaceutical composition thereof for the preparation of a medicament for inhibiting capsid protein assembly.
- the invention provides a compound of formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable thereof, of the present application.
- the invention provides a compound of the above formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate, prodrug or pharmaceutically acceptable salt thereof. Or the use of a pharmaceutical composition thereof for preventing or treating a disease that benefits from inhibition of capsid protein assembly.
- the present application provides a compound of Formula I, a stereoisomer, tautomer, geometric isomer, solvate, active metabolite, hydrate thereof of the present application for inhibiting capsid protein assembly. , a prodrug or a pharmaceutically acceptable salt, or a pharmaceutical composition thereof.
- the present application provides a compound of the above formula I, a stereoisomer, a tautomer, a geometric isomer, a solvate thereof, for the prevention or treatment of a disease which benefits from inhibition of capsid protein assembly.
- the disease that benefits from inhibition of capsid protein assembly refers to a disease caused by hepatitis B virus (HBV) infection.
- HBV hepatitis B virus
- the disease that benefits from inhibition of capsid protein assembly refers to a liver disease caused by hepatitis B virus (HBV) infection.
- HBV hepatitis B virus
- the treatment which benefits from inhibition of capsid protein assembly, refers to controlling, reducing or eliminating HBV to prevent, alleviate or cure liver disease in an infected patient.
- Dotted line in the structural unit or group in the present application Represents a covalent bond.
- a structural unit including but not limited to
- substituted means that any one or more hydrogen atoms on a particular atom are replaced by a substituent as long as the valence of the particular atom is normal and the substituted compound is stable.
- it means that two hydrogen atoms are substituted and the oxo does not occur on the aryl group.
- an ethyl group “optionally” substituted with halo refers to an ethyl group may be unsubstituted (CH 2 CH 3), monosubstituted (e.g., CH 2 CH 2 F), polysubstituted (e.g. CHFCH 2 F, CH 2 CHF 2, etc.) or completely substituted (CF 2 CF 3 ). It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and/or which cannot be synthesized is introduced.
- C mn herein is that the moiety has an integer number of carbon atoms in a given range.
- C1-6 means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
- C 1-3 means that the group may have 1 carbon atom, 2 carbon atoms, and 3 carbon atoms.
- any variable eg, R
- its definition in each case is independent.
- each R has an independent option.
- linking group When the number of one linking group is 0, such as -(CH 2 ) 0 -, it means that the linking group is a covalent bond.
- one of the variables is selected from a covalent bond, it means that the two groups to which it is attached are directly linked.
- L' represents a covalent bond in A-L'-Z, the structure is actually A-Z.
- the substituent When a bond of a substituent is cross-linked to two atoms on a ring, the substituent may be bonded to any atom on the ring.
- a structural unit It is indicated that it can be substituted at any position on the cyclohexyl or cyclohexadiene.
- halo or halogen refers to fluoro, chloro, bromo and iodo.
- alkyl refers to a hydrocarbon group of the formula C n H 2n +.
- the alkyl group can be straight or branched.
- C1-6 alkyl refers to an alkyl group containing from 1 to 6 carbon atoms (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, Tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.).
- alkyl moiety i.e., alkyl
- alkyl of an alkoxy group, an alkylamino group, a dialkylamino group, an alkylsulfonyl group, and an alkylthio group
- C1-3 alkyl refers to an alkyl group containing from 1 to 3 carbon atoms (eg, methyl, ethyl, propyl, and isopropyl).
- alkoxy refers to -O-alkyl
- alkenyl refers to a straight or branched unsaturated aliphatic hydrocarbon group having at least one double bond consisting of a carbon atom and a hydrogen atom.
- alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.
- alkynyl means a straight or branched unsaturated aliphatic hydrocarbon group having at least one triple bond composed of a carbon atom and a hydrogen atom.
- alkynyl groups include, but are not limited to, ethynyl (-C ⁇ CH), 1-propynyl (-C ⁇ C-CH 3 ), 2-propynyl (-CH 2 -C ⁇ CH), 1,3-butadiynyl (-C ⁇ CC ⁇ CH) or the like.
- cycloalkyl refers to a carbocyclic ring that is fully saturated and can exist as a single ring, bridged ring or spiro ring. Unless otherwise indicated, the carbocyclic ring is typically a 3 to 10 membered ring.
- Non-limiting examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, diamond Alkyl, bicyclo[1.1.1]pent-1-yl and the like.
- C 3-4 cycloalkyl includes cyclopropyl and cyclobutyl.
- heterocycloalkyl refers to a cyclic group that is fully saturated and can exist as a monocyclic, bridged or spiro ring. Unless otherwise indicated, the heterocyclic ring is typically a 3 to 7 membered ring containing from 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen and/or nitrogen.
- 3-membered heterocycloalkyl groups include, but are not limited to, oxiranyl, cyclohexylethane, cycloalkylethane, non-limiting examples of 4-membered heterocycloalkyl including, but not limited to, azetidinyl, acetophenan
- Examples of a cyclic group, a thibutyl group, a 5-membered heterocycloalkyl group include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidine
- Examples of the group, imidazolidinyl group, tetrahydropyrazolyl group, 6-membered heterocycloalkyl group include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothio
- aryl refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated ⁇ -electron system.
- an aryl group can have 6-20 carbon atoms, 6-14 carbon atoms or 6-12 carbon atoms.
- Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, 1,2,3,4-tetrahydronaphthalene, and the like.
- heteroaryl refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from N, O, S, the remaining ring atoms being C, and having at least one aromatic ring.
- Preferred heteroaryl groups have a single 4 to 8 membered ring, especially a 5 to 8 membered ring, or a plurality of fused rings containing from 6 to 14, especially from 6 to 10 ring atoms.
- heteroaryl groups include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl , tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, fluorenyl, isodecyl and the like.
- treating means administering a compound or formulation described herein to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes:
- terapéuticaally effective amount means (i) treating or preventing a particular disease, condition or disorder, (ii) alleviating, ameliorating or eliminating one or more symptoms of a particular disease, condition or disorder, or (iii) preventing or delaying The amount of a compound of the present application in which one or more symptoms of a particular disease, condition, or disorder are described herein.
- the amount of a compound of the present application which constitutes a “therapeutically effective amount” will vary depending on the compound, the condition and severity thereof, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art It is determined by its own knowledge and the present disclosure.
- pharmaceutically acceptable is for those compounds, materials, compositions and/or dosage forms that are within the scope of sound medical judgment and are suitable for use in contact with human and animal tissues without Many toxic, irritating, allergic reactions or other problems or complications are commensurate with a reasonable benefit/risk ratio.
- a metal salt, an ammonium salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid, or the like can be mentioned.
- pharmaceutical composition refers to a mixture of one or more compounds of the present application or a salt thereof and a pharmaceutically acceptable adjuvant.
- the purpose of the pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.
- solvate refers to a substance formed by combining a compound of the invention with a pharmaceutically acceptable solvent.
- Pharmaceutically acceptable solvents include water, ethanol, acetic acid, and the like.
- Solvates include stoichiometric amounts of solvates and non-stoichiometric amounts of solvates.
- hydrate refers to a solvate comprising a compound disclosed or claimed and a stoichiometric or non-stoichiometric amount of water.
- the compounds of the invention may also be prepared as prodrugs, such as pharmaceutically acceptable prodrugs. Since prodrugs are known to increase the many desirable properties of the drug (e.g., solubility, bioavailability, preparation, etc.), the compounds of the invention can be delivered in the form of a prodrug. Accordingly, the present invention is intended to encompass prodrugs of currently claimed compounds, methods of delivery thereof, and compositions containing prodrugs.
- prodrug is intended to include any covalently bonded carrier which, when administered to a mammalian subject, releases the active parent drug of the invention in vivo.
- the prodrugs of the present invention are prepared by modifying a functional group present in the compound in such a manner that the modification cleaves into the parent compound in a conventional operation or in vivo.
- the term "individual” includes humans and animals, for example, mammals (e.g., primates, cows, horses, pigs, dogs, cats, mice, rats, rabbits, goats, sheep, birds, etc.).
- mammals e.g., primates, cows, horses, pigs, dogs, cats, mice, rats, rabbits, goats, sheep, birds, etc.
- active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
- pharmaceutically acceptable excipient refers to those excipients which have no significant irritating effect on the organism and which do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water soluble and/or water swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
- tautomer or "tautomeric form” refers to structural isomers of different energies that are interconvertible via a low energy barrier.
- proton tautomers also known as proton transfer tautomers
- proton transfer tautomers include interconversions via proton transfer, such as keto-enol and imine-enamine isomerization.
- a specific example of a proton tautomer is an imidazole moiety in which a proton can migrate between two ring nitrogens.
- Valence tautomers include recombination through some recombination of bonding electrons.
- Certain compounds of the present application may have asymmetric carbon atoms (stereocenters) or double bonds. Thus, racemates, diastereomers, enantiomers, geometric isomers, and individual isomers are included within the scope of the present application.
- the compounds of the present application may exist in specific geometric or stereoisomeric forms. All such compounds are contemplated by the present application, including tautomers, cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers , diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof, and other mixtures, such as enantiomerically or diastereomeric enriched mixtures, All of these are within the scope of this application. Additional asymmetric carbon atoms may be present in the substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are included within the scope of this application.
- optically active (R)- and (S)-isomers as well as the D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present application is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary wherein the resulting mixture of diastereomers is separated and the auxiliary group cleaved to provide purity. The desired enantiomer.
- a diastereomeric salt is formed with a suitable optically active acid or base, followed by conventional methods well known in the art.
- the diastereomers are resolved and the pure enantiomer is recovered.
- the separation of enantiomers and diastereomers is generally accomplished by the use of chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (eg, formation of an amino group from an amine). Formate).
- the present application also includes isotopically labeled compounds of the present application that are identical to those described herein, but in which one or more atoms are replaced by an atomic weight or mass number different from the atomic mass or mass number normally found in nature.
- isotopes that may be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 respectively.
- isotopically-labeled compounds of the present application can be used in compound and/or substrate tissue distribution assays.
- Deuterated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are especially preferred for their ease of preparation and detectability.
- Positron emitting isotopes such as 15 O, 13 N, 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy.
- Isotopically labeled compounds of the present application can generally be prepared by substituting an isotopically labeled reagent for an unisotopically labeled reagent by procedures similar to those disclosed in the schemes and/or examples disclosed below.
- substitution with heavier isotopes such as deuterium (ie, 2 H) can provide certain therapeutic advantages resulting from higher metabolic stability (eg, increased in vivo half-life or reduced dosage requirements), and thus in some cases
- the hydrazine substitution may be partial or complete, and the partial hydrazine substitution means that at least one hydrogen is substituted with at least one hydrazine, and all such forms of the compound are included within the scope of the present application.
- it can be in a structural unit Degenerate on the ground, so as to get concrete And other structures.
- compositions of the present application can be prepared by combining the compounds of the present application with suitable pharmaceutically acceptable excipients, for example, as solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders. , granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols.
- suitable pharmaceutically acceptable excipients for example, as solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders. , granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols.
- Typical routes of administration of a compound of the present application, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, Intramuscular, subcutaneous, intravenous administration.
- the pharmaceutical composition of the present application can be produced by a method well known in the art, such as a conventional mixing method, a dissolution method, a granulation method, a sugar-coating method, a grinding method, an emulsification method, a freeze-drying method, and the like.
- the pharmaceutical composition is in oral form.
- the pharmaceutical compositions can be formulated by admixing the active compound with pharmaceutically acceptable excipients known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, troches, dragees, capsules, liquids, gels, slurries, suspensions and the like for oral administration to a patient.
- Solid oral compositions can be prepared by conventional methods of mixing, filling or tabletting. For example, it can be obtained by mixing the active compound with a solid adjuvant, optionally milling the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to give tablets. Or the core of the sugar coating. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, and the like.
- compositions may also be suitable for parenteral administration, such as sterile solutions, suspensions or lyophilized products in a suitable unit dosage form.
- the therapeutic dose of a compound of the present application can depend, for example, on the particular use of the treatment, the manner in which the compound is administered, the health and condition of the patient, and the judgment of the prescribing physician.
- the proportion or concentration of the compounds of the present application in the pharmaceutical compositions may not be fixed, depending on a variety of factors including dosage, chemical characteristics (e.g., hydrophobicity) and route of administration.
- the compound of the present application can be provided for parenteral administration by a physiologically buffered aqueous solution containing about 0.1 to 10% w/v of the compound.
- Some typical dosages range from about 1 [mu]g/kg to about 1 g/kg body weight per day.
- the dosage ranges from about 0.01 mg/kg to about 100 mg/kg body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or condition, the general state of health of the particular patient, the relative biological effectiveness of the selected compound, the excipient formulation, and the route of administration thereof.
- An effective dose can be obtained by extrapolation from a dose-response curve derived from an in vitro or animal model test system.
- the compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, combinations thereof with other chemical synthesis methods, and those well known to those skilled in the art. Equivalent alternatives, preferred embodiments include, but are not limited to, embodiments of the present application.
- the compounds of formula (I) of the present application can be prepared by one of ordinary skill in the art of organic synthesis by general or conventional methods in the art by the following routes:
- R 6 and R 9 are selected from methyl or ethyl.
- NBS stands for N-bromosuccinimide
- EA stands for ethyl acetate
- PE stands for petroleum ether
- NCS N-chlorosuccinimide
- DMF stands for N,N-dimethylformamide
- HATU stands for 2- 7-Oxobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
- h stands for hour
- DCM stands for dichloromethane
- DIPEA stands for N,N-diisopropyl
- DMA stands for dimethylacetamide
- THF stands for tetrahydrofuran
- LiHDMS stands for bistrimethylsilylamine lithium
- PO stands for oral
- IV stands for intravenous injection
- MRT stands for mean residence time
- Ts stands for p-toluenesulfonyl
- the instrument used for mass spectrometry is AB SCIEX Triple TOF 4600 or AB SCIEX 3200QTRAP.
- Step A Under a nitrogen atmosphere, add DMF (100 mL), 2,4-dimethyl-1H-pyrrole-3-carboxylate (8.0 g), methyl iodide (8.15 g) to a 500 mL vial, under ice bath. Add sodium hydride (2.87g) in portions, add to the room temperature and react for 2.5h. After the reaction is finished, slowly pour into 400mL of ice water to quench, extract with ethyl acetate (2 * 300mL), and combine the organic layer with saturated The organic layer was washed with an aqueous solution of sodium chloride, and the organic layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure.
- Step B In a 500 mL three-necked flask, under nitrogen, add THF (150 mL), 1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (15.0 g), 5-amino-2-fluoro Benzonitrile (14.08 g) was slowly added dropwise with bis(trimethylsilyl)amide lithium (27.7 g, 166 mL of THF solution) under ice-cooling, and then transferred to room temperature for 16.0 h. After the reaction was completed, it was slowly poured into 500 mL of ice water, and the mixture was evaporated. EtOAc (EtOAc m.
- Step C Under a nitrogen atmosphere, add DCM (240 mL) to a 500 mL vial, (N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-1H-pyrrole-3- Formamide (5.0 g), monoethyl chloroacetonate (7.55 g), add aluminum chloride (12.29 g) in portions under ice-cooling, transfer to room temperature for 15.0 h after the addition. After the reaction, slowly pour into 300 mL of ice water. The mixture was extracted with EtOAc (EtOAc m.
- Step D In a 100 mL single-necked flask, methanol (30 mL), 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl A solution of ethyl-1H-pyrrol-2-yl)-2-oxoacetate (4.00 g) and sodium hydroxide (0.862 g) in water (30 mL). Water (200 mL) and DCM (150 mL) were added to the reaction mixture, and the layers were separated, and the organic layer was evaporated. The aqueous layer was adjusted to pH 2 with concentrated hydrochloric acid and extracted with ethyl acetate (2*150 mL).
- Step E DMF (5.0 mL), 2-(4-(3-cyano-4-fluorophenyl)carbamoyl)-1,3,5-trimethyl-1H- was added sequentially to a 50 mL vial. Pyrrol-2-yl)-2-oxoacetic acid (300 mg), HATU (399 mg), DIPEA (169 mg).
- trans-3-aminocyclobutanol hydrochloride was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl)-5-(2-(( Trans-3-hydroxycyclobutyl)amino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide.
- Example 1 in the step E, 2-aminoisobutyric acid methyl ester hydrochloride was used in place of propargylamine to obtain (2-(4-(3-cyano-4-fluorophenyl)carbamoyl)). Methyl-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetylamino)-2-methylpropanoate.
- Example 1 in the step E, cis-3-amino-cyclobutane methanol was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl)-5-(2-(( 3-(Hydroxymethyl)cyclobutyl)amino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide.
- Example 1 (R)-N-(3-cyano-4-fluorophenyl) was obtained by substituting (R)-1,1,1-trifluoroisopropylamine hydrochloride for propargylamine in step E. -1,2,4-trimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3- Formamide.
- Step A According to Example 1, (S)-N-(3-cyano-4-) was prepared by substituting (S)-1,1,1-trifluoroisopropylamine hydrochloride for propargylamine in step E. Fluorophenyl)-1,2,4-trimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole -3-carboxamide.
- Step A In a 500 mL single-mouth bottle, under DC protection, add DCM (250 mL), ethyl 1,2,4-trimethyl-1H-pyrrole-3-carboxylate (2.0 g), monoethyl chloroacetonate (4.52) g). Under ice bath, anhydrous aluminum chloride (7.36 g) was slowly added, and after completion, it was transferred to room temperature for 5.5 h. After the completion of the reaction, the mixture was poured into 200 mL of ice water, and the mixture was evaporated.
- Step B In a 100 mL single-mouth bottle, add methanol (10 mL), ethyl 5-(2-ethoxy-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylate (1.20 g), a solution of sodium hydroxide (0.34 g) in water (10 mL) was slowly added, and the mixture was reacted for 15 minutes in an ice bath. After the completion of the reaction, water (30 mL) was added to the reaction mixture, and the mixture was combined with EtOAc EtOAc. The solvent was evaporated under reduced pressure to give diethyl 2-(4-(ethoxycarbonyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (897 mg). In the next step.
- Step D In a 50 mL single-mouth bottle, methanol (9 mL), 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3 was added in sequence. Ethyl formate (500 mg), a solution of sodium hydroxide (259 mg) in water (9 mL) was added at room temperature, and the mixture was heated to 90 ° C for 3.0 h.
- EtOAc EtOAc (2-(tert-Butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid (260 mg) was used directly in the next step.
- 1 H-NMR 500MHz, DMSO -d6): ⁇ 12.28 (s, 1H), 8.26s, 1H), 3.73 (s, 3H), 2.50 (s, 3H), 2.38 (s, 3H), 1.33 ( s, 9H).
- Step E Toluene (15 mL), 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3 was added sequentially to a 50 mL single-necked flask. - Formic acid (360 mg), thionyl chloride (3.05 g), the system was heated to 115 ° C for 1.0 h under nitrogen. After the reaction was completed, the mixture was cooled to room temperature, and the solvent was evaporated to remove the acid chloride intermediate (339 mg).
- Step A Substituting methyl 2-methyl-1H-pyrrole-3-carboxylate for ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate according to Example 1 to obtain 1,4 Methyl dimethyl-1H-pyrrole-3-carboxylate.
- Step B Substituting methyl 1, 4-dimethyl-1H-pyrrole-3-carboxylate for 1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid B in step A according to Example 13. Ester to give methyl 5-(2-ethoxy-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylate. MS (ESI+, [M+Na] + ) m/z: 276.3.
- Step C Substituting 5-(2-ethoxy-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl ester for 5- in step B according to Example Ethyl 2-(2-ethoxy-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylate to give 2-(4-(methoxycarbonyl)-1 , 3-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid.
- Step D Substituting 2-(4-(methoxycarbonyl)-1,3-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid for 2- in step C according to Example 13. (4-(ethoxycarbonyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid to give 5-(2-(tert-butylamino)-2 Methyl oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylate.
- Step E According to Example 13, methyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylate was used in Step D Substituting ethyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylate to give 5-(2-(uncle) Butylamino)-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylic acid.
- Step F Substituting 5-(2-(tert-butylamino)-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylic acid in step E according to Example 13.
- 5-(2-(tert-Butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid to give 5-(2-(tert-butylamino) 2-oxoacetyl)-N-(3-cyano-4-fluorophenyl)-1,4-dimethyl-1H-pyrrole-3-carboxamide.
- Step A According to Example 1, in step A, ethyl 2-methyl-1H-pyrrole-3-carboxylate was used in place of ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate to obtain 1, Ethyl 2-dimethyl-1H-pyrrole-3-carboxylate.
- Step B Substituting 1,2-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester for 1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid in step A according to Example 13. Ethyl ester gave ethyl 5-(2-ethoxy-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate.
- Step C According to Example 13, in step B, 5-(2-ethoxy-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester was used instead of 5- Ethyl 2-(2-ethoxy-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylate to give 2-(4-(ethoxycarbonyl)-1 , 5-Dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid.
- Step D Substituting 2-(4-(ethoxycarbonyl)-1,5-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid for 2- in step C according to Example 13. (4-(ethoxycarbonyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid to give 5-(2-(tert-butylamino)-2 -Oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester.
- Step E According to Example 13, in step D, ethyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylate Substituting ethyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxylate to give 5-(2-(uncle) Butylamino)-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid. MS (ESI - , [MH] - ) m / z: 265.3.
- Step F Substituting 5-(2-(tert-butylamino)-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid in step E according to Example 13.
- Step A To the reaction flask, 1H-pyrrole-3-carboxylic acid methyl ester (3.0 g) and 20 mL of DMF were sequentially added. After dissolving, 1.16 g of sodium hydride was added in portions at 0 ° C, and 1.67 mL of methyl iodide was added thereto. After the reaction at room temperature for 0.5 h. After the completion of the reaction, 50 mL of water and 50 mL of LDCM were added, and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give methyl 1-methyl-1H-pyrrole-3-carboxylate (3.12 g) Purification was used directly in the next reaction.
- Step C To the reaction flask, methyl 5-(2-ethoxy-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylate (3.35 g), THF (4 mL) After stirring at room temperature for 10 minutes, a solution of sodium hydroxide (1.68 g) in water (4.00 ml) was slowly added thereto, and the mixture was reacted at room temperature for 1 hour. After the completion of the reaction, the pH of the solution was adjusted to 3 to 4, 50 mL of ethyl acetate and 50 mL of purified water were added, the organic layer was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 2-(4-(methoxycarbonyl).
- Step D To the reaction flask, 2-(4-(methoxycarbonyl)-1-methyl-1H-pyrrol-2-yl)-2-oxoacetic acid (2.46 g), ethyl acetate 2 mL), tert-butylamine (2.55 g) and 1-propylphosphoric anhydride (50% w/v ethyl acetate solution, 7.5 mL) were reacted at room temperature for 1 hour. After the reaction was completed, 100 mL of ethyl acetate and 100 mL of water were added thereto.
- Step E To the reaction flask, methyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylate (1.17 g), methanol (5 mL), after stirring for 10 minutes, a solution of sodium hydroxide (0.53 g) in water (5.00 ml) was added, and the mixture was reacted at room temperature for 1 hour. After completion of the reaction, the pH was adjusted to 3 to 4 with 2N HCl, and 100 mL of ethyl acetate and 100 mL of water were added.
- Step F To the reaction flask, 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylic acid (100 mg), toluene (2 mL) Sulfoxide (189 mg), under N 2 protection, heated to 110 ° C for 1 h. The solvent was removed by concentration, and N,N-dimethylacetamide (2 mL) and 5-amino-2-fluorophenylacetonitrile (108 mg) were added to the obtained crude product, and the mixture was heated to 100 ° C for 2 h.
- Step A 100 mg of 5-(2-(tert-butylamino-2-oxoacetyl)-N-(3-cyano-4-fluorophenyl)-1-methyl-1H was sequentially added to the reaction flask. - Pyrrole-3-carboxamide, 1 mL of DMF, 4 mL of acetonitrile and 48.1 mg of NBS, and reacted at 80 ° C for 24 hours. After the reaction was completed, 100 mL of ethyl acetate and 100 mL of water were added thereto, and the organic phase was separated, and brine (2*50 mL) was used. Washed, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated.
- Step A To the reaction flask was added 100 mg of 5-(2-(tert-butylamino-2-oxoacetyl)-N-(3-cyano-4-fluorophenyl)-1-methyl-1H- Pyrrole-3-carboxamide, 1 mL of DMF and 4 mL of acetonitrile were added, and 144.3 mg of NBS was added thereto, and the mixture was reacted at 110 ° C for 24 hours. The stirring was stopped, and 100 mL of ethyl acetate and 100 mL of water were added to the solution. The organic phase was separated and saturated brine was used.
- Example 1 in the step E, tetrahydro-4-methyl-2H-pyran-4-amine was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl)-1,2. 4-Trimethyl-5-(2-((4-methyltetrahydro-2H-pyran-4-yl)amino)-2-oxoacetyl)-1H-pyrrole-3-carboxamide.
- Example 1 in the step E, 3-(trifluoromethyl)oxetan-3-amine hydrochloride was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl). -1,2,4-trimethyl-5-(2-oxo-2-((3-(trifluoromethyl)oxetan-3-yl)amino)acetyl)-1H-pyrrole -3-carboxamide.
- Example 1 in the step E, 3(3-aminooxetan-3-yl)methanol was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl)-5-( 2-(3-(Hydroxymethyl)oxetan-3-yl)amino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide.
- Example 1 in the step E, (1-aminocyclopropyl)methanol was used in place of propargylamine to obtain N-(3-cyano-4-fluorophenyl)-5-(2-((1-( Hydroxymethyl)cyclopropyl)amino)-2-oxoacetyl)-1,2,4-trimethyl-1H-pyrrole-3-carboxamide.
- Step A At 0 ° C, water (10.00 mL) and sodium hydroxide (1.416 g) were sequentially added to the reaction flask, and 1-amino-3,3-difluorocyclobutane-1-carboxylic acid (5 g) was slowly added dropwise. A solution of methanol (50 mL) was added dropwise, then di-tert-butyl dicarbonate (9.10 g) was added. After the addition, the mixture was stirred at room temperature for 16 h. After the reaction was finished, the pH was adjusted to 2 to 3 with 2N HCl and filtered.
- Step B 1-((tert-Butoxycarbonyl)amino)-3,3-difluorocyclobutane-1-carboxylic acid (7.6 g), HATU (17.25 g), DMF (50 mL) were sequentially added to the reaction flask. ), methylamine (4.79 g) and DIPEA (42.3 mL) were reacted at room temperature for 3 h.
- Step C To the reaction flask, t-butyl (3,3-difluoro-1-(methylcarbamoyl)cyclobutyl)carbamate (7.38 g) and dioxane (50 mL) were added successively. 4M HCl in dioxane solution (69.8 mL) was added dropwise and stirred at room temperature for 12 h. After the reaction, the pH was adjusted to 10-11 with 2M sodium hydroxide solution, filtered, and the filter cake was dried under vacuum at 40 ° C to give 1-amino-3,3-difluoro-N-methylcyclobutane-1-carboxamide salt. Acid salt (5.19 g).
- Step D According to Example 1, in the step E, 1-amino-3,3-difluoro-N-methylcyclobutane-1-carboxamide hydrochloride was used in place of propargylamine to obtain N-(3- Cyano-4-fluorophenyl)-5-(2-((3,3-difluoro-1-(methylcarbamoyl)cyclobutyl)amino)-2-oxoacetyl)-1, 2,4-Trimethyl-1H-pyrrole-3-carboxamide.
- Step A DMF (100 mL), 4-methyl-1H-pyrrole-3-carboxylic acid ethyl ester (20 g) was added to the reaction flask, and NaH (7.83 g) was slowly added under N 2 protection. After the addition was completed, stirring for 30 min, slowly adding methyl iodide (23.17 g) to the above stirred solution, adding, stirring at room temperature for 2.0 h, pouring the reaction solution into saturated ammonium chloride solution (1000 mL) containing crushed ice, using acetic acid The ester was extracted (3*1000 mL). EtOAcjjjjjjjjjj .
- Step B Add 1,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (10 g) and DCM (200 mL) to the reaction flask, and then add AlCl 3 (32 g) under ice bath, and add, Under N 2 protection, a solution of oxalyl chloride (24.5 g) in DCM (100 mL) was added dropwise, and the mixture was stirred at room temperature for 5.0 h. The reaction solution was poured into 500 mL of ice water and extracted with DCM (200 mL*3).
- Step C To the reaction flask was added ethyl 5-(2-ethoxy-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylate (6 g), DMF (100 mL) , NCS (4.5 g), and stirred at room temperature for 8.0 h. The reaction mixture was poured into 500 mL of water, and extracted with ethyl acetate (200 mL*3).
- Step D To the reaction flask was added ethyl 2-chloro-5-(2-ethoxy-2-oxoacetyl)-1,4-dimethyl-1H-pyrrole-3-carboxylate (3.2 g ), methanol (30mL), NaOH (0.85g) aqueous solution (10mL) was added dropwise in an ice bath, added, stirred at room temperature, reacted for 5min, adjusted to pH 2-3 with 2N HCl, with ethyl acetate (100mL*3) The organic layer was combined, washed with saturated brine, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated to dry to give 2-(5-chloro-4-(ethoxycarbonyl)-1,3-dimethyl-1H -pyrrol-2-yl)-2-oxoacetic acid (2.6 g). MS (ESI-, [MH] - ) m/z: 272.1.
- Step E adding 2-(5-chloro-4-(ethoxycarbonyl)-1,3-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (400 mg) to the reaction flask, DMF (10 mL), HATU (834 mg), DIPEA (416 mg), added, stirred at room temperature for 10 min, then added (S)-1,1,1-trifluoroisopropylamine hydrochloride (200 mg), and stirred at room temperature 2.0 h, the reaction solution was poured into 100 mL of water, and extracted with ethyl acetate (50 mL*3).
- Step F Add (S)-2-chloro-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)) to the reaction flask
- Ethylamino)acetyl)-1H-pyrrole-3-carboxylic acid ethyl ester 360 mg
- methanol (20 mL) were added
- NaOH (0.85 g) aqueous solution (5 mL) was added dropwise, and the mixture was reacted at 80 ° C for 8.0 h.
- the pH was adjusted to 2 to 3 with 2N HCl, and extracted with ethyl acetate (100 mL*3).
- Step G Add (S)-2-chloro-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)) to the reaction flask Amino)acetyl)-1H-pyrrole-3-carboxylic acid (320 mg), toluene (10 mL) and thionyl chloride (2.3 g), added, and reacted at 115 ° C for 2.0 h under N 2 protection. The crude product was obtained, and DMA (10 mL) and 5-amino 2-fluorobenzonitrile (256 mg) were added thereto, and the mixture was reacted at 100 ° C for 2.0 h.
- Step A According to Example 29, in the step E, (R)-1,1,1-trifluoroisopropylamine hydrochloride was used in place of (S)-1,1,1-trifluoroisopropylamine hydrochloride. (R)-2-Chloro-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H - ethyl pyrrole-3-carboxylate.
- Step B According to Example 29, in step F, (R)-2-chloro-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoropropane) Ethyl 2-amino)amino)acetyl)-1H-pyrrole-3-carboxylate in place of (S)-2-chloro-1,4-dimethyl-5-(2-oxo-2-(( Ethyl 1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate, (R)-2-chloro-1,4-dimethyl-5 -(2-Oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylic acid.
- Step C According to Example 29, in step G, ((R)-2-chloro-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoro)) Replacement of (S)-2-chloro-1,4-dimethyl-5-(2-oxo-2-(1) with propan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylic acid ,1,1-Trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylic acid, (R)-2-chloro-N-(3-cyano-4-fluorobenzene) ))-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-yl 1 H NMR (500 MHz, DMSO-d 6 ): ⁇ 10.58 (s, 1H), 9.51 -
- Step A To the reaction flask were added 1,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (40 g), 5-fluoro-2-aminobenzonitrile (40.7 g), THF (200 ml), ice LiHDMS in THF (1M, 600 mL) was added to the mixture, and the mixture was stirred at room temperature for 2 h. The reaction solution was poured into ice water (1500 mL) containing saturated ammonium chloride solution, and a large amount of solid was precipitated and filtered.
- Step B Add zinc oxide (4.11 g) to the reaction flask, add oxalyl chloride monoethyl ester (310 g) under ice bath, and then add N-(3-cyano-4-fluorophenyl)-1,4-di Methyl-1H-pyrrole-3-carboxamide (26 g), stirred in an ice bath for 20 min, stirred at room temperature for 3.0 h, added DCM (300 ml) to the reaction mixture under ice-cooling for 30 min, then poured into the ice water The mixture was extracted with EtOAc (3 mL) (EtOAc m.
- Step C Add 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3-dimethyl-1H-pyrrol-2-yl)-2- to the reaction flask Ethyl acetate (10 g) and DMF (400 mL) were added, and NCS (4.86 g) was dissolved in DMF (20 mL), and then added dropwise to the reaction mixture, and the mixture was stirred at room temperature for 30 hours, and the reaction solution was poured into 1000 mL of water.
- Step D Add 2-(5-chloro-4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3-dimethyl-1H-pyrrol-2-yl to the reaction flask Ethyl 2-oxoacetate (4 g), THF (100 mL), EtOAc (EtOAc, EtOAc (EtOAc) 4, extracted with ethyl acetate (100 mL * 3), the organic layer was combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 2-(5-chloro-4-((3-cyano-4-) Fluorophenyl)carbamoyl)-1,3-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (3.0 g).
- Step E Add 2-(5-chloro-4-((3-cyano-4-fluorophenyl)carbamoyl)-1,3-dimethyl-1H-pyrrol-2-yl to the reaction flask 2-oxoacetic acid (150 mg), DMF (6 mL), HATU (235 mg), DIPEA (160 mg), stirring at room temperature for 5 min, then 4-methyltetrahydro-2H-pyran-4-amine (50 mg). After reacting at room temperature for 2.0 h, 50 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (60 mL*3).
- Step A Substituting 3-(tetrafluoromethyl)oxetan-3-amine hydrochloride for 4-methyltetrahydro-2H-pyran-4-amine according to Example 31, Preparation of 2-chloro-N-(3-cyano-4-fluorophenyl)-1,4-dimethyl-5-(2-oxo-2-((3-(trifluoromethyl))oxy) Heterocyclobutane-3-yl)amino)acetyl)-1H-pyrrole-3-carboxamide.
- Step A According to Example 31, in the step E, 2-amino-2-methylpropan-1-ol was used in place of 4-methyltetrahydro-2H-pyran-4-amine to give 2-chloro-N. -(3-cyano-4-fluorophenyl)-5-(2-((1-hydroxy-2-methylpropan-2-yl)amino)-2-oxoacetyl)-1,4- Dimethyl-1H-pyrrole-3-carboxamide.
- Step A According to Example 31, in the step E, 3-methyl-aminooxetane was used instead of 4-methyltetrahydro-2H-pyran-4-amine to give 2-chloro-N- (3-cyano-4-fluorophenyl)-1,4-dimethyl-5-(2-((3-methyloxetan-3-yl)amino)-2-oxoacetyl Base)-1H-pyrrole-3-carboxamide.
- Step A According to Example 29, in the step G, 3-chloro-4-fluoroaniline was substituted for 5-amino-2-fluorobenzonitrile to obtain (S)-2-chloro-N-(3-chloro-4). -fluorophenyl)-1,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole- 3-formamide.
- Step A To the reaction flask, 2-(4-(ethoxycarbonyl)-1,3,5-trimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (800 mg, 3.16) was added in order. Methyl acetate (5 ml) was stirred for 10 min, then N,N-diisopropylethylamine (1225 mg, 1.66 ml, 9.48 mmol), HATU (1441 mg, 3.79 mmol). 100 mL of ethyl acetate and 100 mL of water were added to the solution, and the organic phase was separated.
- Step B sequentially adding 1,2,4-trimethyl-5-(2-((4-methyltetrahydro-2H-pyran-4-yl)amino)-2-oxo to the reaction flask
- Ethyl acetyl)-1H-pyrrole-3-carboxylic acid ethyl ester (954 mg, 2.72 mmol)
- methanol 8 ml
- water 8.00 ml
- sodium hydroxide 0.327 g, 8.17 mmol
- the solution was treated with N 2 and allowed to react at room temperature for 1 hour.
- the pH of the solution was adjusted to 3 to 4, and 200 mL of ethyl acetate and 200 mL of purified water were added to the reaction.
- Step C To the reaction flask, 1,2,4-trimethyl-5-(2-((4-methyltetrahydro-2H-pyran-4-yl)amino)-2-oxo was added sequentially.
- Acetyl)-1H-pyrrole-3-carboxylic acid (280 mg), toluene (5 ml), thionyl chloride (0.25 ml, 3.47 mmol), and reacted at 115 ° C for 1 hour under N 2 . After concentration, 5.0 mL of toluene was added to the residue and concentrated to give 268 mg.
- Example 37 3-chloro-4-fluoroaniline was replaced with 4-fluoroaniline to obtain (S)-N-(4-fluorophenyl)-1,2,4-trimethyl-5-(2 - Oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxamide.
- Step A According to Example 37, (S)-N-(3-amino-4-fluoro) was obtained by substituting 4-fluorobenzene-1,3-diamine for 3-chloro-4-fluoroaniline in Step A. Phenyl)-1,2,4-trimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole- 3-formamide.
- Example 1 in the step E, 1-propanolamine was replaced with 1-methylpiperazine to obtain N-(3-cyano-4-fluorophenyl)-1,2,4-trimethyl-5-. (2-(4-Methylpiperazin-1-yl)-2-oxoacetyl)-1H-pyrrole-3-carboxamide.
- Example 1 in the step E, 3-amino-3-methylthietane 1,1-dioxide was substituted for propargylamine to obtain N-(3-cyano-4-fluorophenyl). -1,2,4-trimethyl-5-(2-((3-methyl-1,1-dithio-3-yl)amino)-2-oxoacetyl)-1H-pyrrole-3 - Formamide.
- Step A According to Example 1, 3,4,5-trifluoroaniline in Step B was substituted for 5-amino-3-fluorobenzonitrile to obtain 1,2,4-trimethyl-N-(3, 4,5-Trifluorophenyl)-1H-pyrrole-3-carboxamide.
- Step B Add monoethyl chloroacetonate (447 g), zinc oxide (5.28 g) to the reaction flask, and add 1,2,4-trimethyl-N-(3,4,5-three in portions under ice bath. Fluorophenyl)-1H-pyrrole-3-carboxamide (36.6 g) was added to room temperature and stirred for 2.0 h. After the reaction was completed, it was poured into 500 mL of ice water and quenched, and extracted with DCM (2*500 mL). The organic layer was evaporated.
- Step C Under ice bath, MeOH (120 mL), 2-oxo-2-(1,3,5-trimethyl-4-) (3,4,5-trifluorophenyl) was added to the reaction flask. A solution of carbamoyl)-1H-pyrrol-2-yl)acetate (28.8 g) and sodium hydroxide (6.93 g) in water (60 mL), Water (200 mL) and DCM (150 mL) were added to the reaction mixture, and the layers were separated, and the organic layer was evaporated. The aqueous layer was adjusted to pH 3 with concentrated hydrochloric acid and extracted with ethyl acetate (2*500 mL).
- Step D sequentially add DMF (5.0 mL), 2-oxo-2-(1,3,5-trimethyl-4-((3,4,5-trifluorophenyl))aminocarbamide to the reaction flask.
- DMF 5.0 mL
- 2-oxo-2-(1,3,5-trimethyl-4-((3,4,5-trifluorophenyl))aminocarbamide 5.0 mL
- Acyl)-1H-pyrrol-2-yl)acetic acid 600 mg
- DIPEA (657 mg)
- 3-methyl-3-butylbutylamine (162 mg).
- Step A According to Example 18, (S)-1,1,1-trifluoropropan-2-amine hydrochloride was used in step D instead of t-butylamine to give (S)-1-methyl-5- ( Methyl 2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate. MS (ESI+, [M+H] + ) m/z: 307.2.
- Step B According to Example 18, in step E, (S)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino) Methyl acetyl)-1H-pyrrole-3-carboxylate in place of methyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylate, (S)-1-Methyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate acid.
- Step C According to Example 18, in step F, (S)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino) Acetyl)-1H-pyrrole-3-carboxylic acid in place of 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylic acid, S)-N-(3-Cyano-4-fluorophenyl)-1-methyl-5-(2-oxo-2-(1,1,1-trifluoroprop-2-yl)amino) Acetyl)-1H-pyrrole-3-carboxamide.
- Step A According to Example 18, (R)-1,1,1-trifluoropropan-2-amine hydrochloride was used in step D instead of t-butylamine to give (R)-1-methyl-5- ( Methyl 2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate. MS (ESI-, [MH] - ) m/z: 305.3.
- Step B According to Example 18, in step E, (R)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino) Methyl acetyl)-1H-pyrrole-3-carboxylate in place of methyl 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylate, Preparation of (R)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate acid. MS (ESI-, [MH] - ) m/z: 291.3.
- Step C According to Example 18, in step F, (R)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino) Acetyl)-1H-pyrrole-3-carboxylic acid in place of 5-(2-(tert-butylamino)-2-oxoacetyl)-1-methyl-1H-pyrrole-3-carboxylic acid, R)-N-(3-Cyano-4-fluorophenyl)-1-methyl-5-(2-oxo-2-(1,1,1-trifluoropropan-2-yl)amino) Acetyl)-1H-pyrrole-3-carboxamide.
- Step A In the reaction flask, methyl 1-methyl-1H-pyrrole-3-carboxylate (33 g), 2-fluoro-5-aminobenzonitrile (40.4 g), tetrahydrofuran (200 mL), Lithium bis(trimethylsilyl)amide (90 g, 538 mL of tetrahydrofuran solution) was added, and after 30 minutes, the reaction mixture was warmed to room temperature and stirred for 1 hour. After the reaction was completed, the reaction solution was poured into 2000 mL of ice water, stirred vigorously for 10 minutes, filtered, and the filter cake was dried overnight to give N-(3-cyano-4-fluorophenyl)-1-methyl-1H-pyrrole-3. - formamide (51.48 g).
- Step B Add N-(3-cyano-4-fluorophenyl)-1-methyl-1H-pyrrole-3-carboxamide (20.0 g), dichloromethane (250 mL), and then stirred. Ethyl 2-chloro-2-oxoacetate (33.7 g), anhydrous aluminum trichloride (10.96 g) was added portionwise, and then transferred to room temperature for 2 hours. After the reaction was completed, the reaction mixture was poured into 2,000 mL of ice water, and the mixture was evaporated.
- Step C Add 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1-methyl-1H-pyrrol-2-yl)-2-oxoacetic acid to the reaction flask Ethyl ester (2.16g), tetrahydrofuran (10mL), the reaction solution was placed in an ice bath, lithium hydroxide monohydrate (0.53g) was dissolved in water (5mL), and the mixture was stirred in an ice bath.
- reaction was carried out for 30 minutes, and after completion of the reaction, it was diluted with 50 mL of water, adjusted to pH 5-6 with 2 mol/L of diluted hydrochloric acid, washed with ethyl acetate (50 mL*3), dried and concentrated to give 2-(4-((3- Cyano-4-fluorophenyl)carbamoyl)-1-methyl-1H-pyrrol-2-yl)-2-oxoacetic acid (1.03 g) was used directly in the next step.
- Step D In the reaction flask, 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-1-methyl-1H-pyrrol-2-yl)-2-oxo was added sequentially.
- Acetic acid 0.2 g
- 3-(trifluoromethyl)oxetan-3-amine hydrochloride (0.169 g)
- HATU 0.362 g
- N,N-dimethylformamide 5 mL
- DIPEA 0.246 g
- Example 51 5-(2-(tert-butylamino)-2-oxoacetyl)-N-(3-cyano-4-fluorophenyl)-1-methyl-1H-pyrrole- Replacement of 3-formamide with (S)-N-(3-cyano-4-fluorophenyl)-1-methyl-5-(2-oxo-2-((1,1,1-trifluoro) (2-)-N-(3-cyano-4-fluorophenyl)-2-fluoro-1-methyl 5-(2-Oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxamide.
- Example 51 5-(2-(tert-butylamino)-2-oxoacetyl)-N-(3-cyano-4-fluorophenyl)-1-methyl-1H-pyrrole- 3-formamide is replaced by (S)-N-(3-cyano-4-fluorophenyl)-1,4-dimethyl-5-(2-oxo-2-((1,1,1) -Trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxamide to give (S)-N-(3-cyano-4-fluorophenyl)-2-fluoro-1 4-Dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)amino)acetyl)-1H-pyrrole-3-carboxamide.
- Step A Under a nitrogen atmosphere, (1S,4S)-quinuclidin-3-ol (113 mg), tetrahydrofuran (1.5 mL), ethyl butyl-2,3-dienoate (500 mg) was added to the reaction flask.
- Acetaldehyde (392 mg, 1.7 mL tetrahydrofuran solution) was added to the ice salt bath, and the system was reacted at -10 ° C for 5.0 h. After the addition, the mixture was transferred to room temperature for 2.5 h. After the reaction was completed, it was slowly poured into 20 mL of ice water and quenched with acetic acid.
- Step B Under a nitrogen atmosphere, add dichloromethane (10.0 mL), ethyl 2-(1-hydroxyethyl)butane-2,3-dienoate (210 mg) to the reaction flask, and add 4- Methylbenzenesulfonyl isocyanate (292 mg), after the addition, was transferred to room temperature for 1.0 h. After the reaction was completed, it was slowly poured into 50 mL of ice water and quenched, extracted with DCM (2*50 mL). The organic layer was washed with an aqueous solution, and the organic layer was dried over anhydrous sodium sulfate.
- Step C Under a nitrogen atmosphere, benzene (8.0 mL), ethyl 2-(1-((toluenesulfonylamino)oxy)ethyl)butane-2,3-dienoate (270 mg) was added to the reaction flask. A solution of 1,4-diazabicyclo[2.2.2]octane (83 mg) in benzene (8.0 mL) was slowly added dropwise at room temperature. The dropwise addition was continued for 5.0 h, and the reaction was carried out for 16.0 h after the completion of the reaction. The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate.
- Step D To a 250 ml single-necked flask was added diethyl ether (80 mL), ethyl 2-(1-((4-methylphenyl)sulfonylamino)ethyl)butane-2,3-dienoate, under nitrogen. (6.26 g), N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (9.57 g), silver nitrate (0.687 g), potassium carbonate (5.59 g). The reaction mixture was poured into water (100 ml), and the mixture was evaporated.
- PE: EA 4:1
- Step F DMF (20 mL), ethyl 4-fluoro-2-methyl-1H-pyrrole-3-carboxylate (0.2 g), iodomethane (199 mg) was added to the reaction flask, and sodium hydrogen was slowly added to the ice bath. (56mg). After the reaction was completed, the mixture was stirred at room temperature for 1.0 h. After the reaction was completed, the reaction mixture was poured into ice water (50 mL), and ethyl acetate (50 mL*2) was used to extract the organic layer, and the organic layer was washed with saturated brine. The organic phase was dried over sodium sulfate, and the solvent was evaporated under reduced pressure.
- Step G To the reaction flask was added tetrahydrofuran (12 mL), ethyl 4-fluoro-1,2-dimethyl-1H-pyrrole-3-carboxylate (200 mg), 5-amino-2-fluorobenzonitrile (170 mg) Lithium bis(trimethylsilyl)amide (415 mg, 2.7 mL tetrahydrofuran solution) was slowly added under ice bath. After the reaction was completed, the mixture was stirred at room temperature for 2.0 h. After the reaction was completed, the reaction mixture was poured into ice water (50 mL), ethyl acetate (50 mL*2), and the organic layer was combined.
- Step H Under the protection of nitrogen, zinc oxide (20 mg), monoethyl chloroacetonate (1.38 g) was added to the reaction flask, and N-(3-cyano-4-fluorophenyl)-4 was added in portions under ice bath. -Fluoro-1,2-dimethyl-1H-pyrrole-3-carboxamide (140 mg), which was reacted for 2.0 h after the addition. After the reaction was completed, it was slowly poured into 50 mL of ice water and quenched, and extracted with DCM (2*50 mL). The organic layer was evaporated.
- Step I To a reaction flask, tetrahydrofuran (3.0 mL), 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-3-fluoro-1,5- Dimethyl-1H-pyrrol-2-yl)-2-oxoacetate (120 mg), a solution of lithium hydroxide monohydrate (19.2 mg) in water (5.0 mL) was added dropwise. Reaction for 10 minutes. Water (40 mL) and ethyl acetate (30 mL) were added to the mixture, and the layers were separated. The organic layer was evaporated.
- Step J N,N-dimethylformamide (5.0 mL), 2-(4-(3-cyano-4-fluorophenyl)carbamoyl)-3-fluoro-1 was added sequentially to the reaction flask. ,5-Dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (38.0 mg), HATU (54 mg), DIPEA (32.5 mg), then (S)-1,1,1-three Fluorin-2-amine hydrochloride (20 mg) was stirred at room temperature for 2.0 h. Water (50 mL) was added to the reaction mixture, and the mixture was evaporated.
- Step A To the reaction flask was added N,N-dimethylformamide (15 mL), 5-(2-ethoxy-2-oxoacetyl)-1,2-dimethyl-1H-pyrrole- 3-carboxylic acid ethyl ester (1.0 g), 1-chloropyrrolidine-2,5-dione (0.6 g), was reacted at room temperature for 24.0 h.
- Step B Under ice bath, MeOH (9.0 mL), 2-(chloromethyl)-5-(2-ethoxy-2-oxoacetyl)-1-methyl-1H was added to the reaction flask. A solution of ethyl pyrrole-3-carboxylate (1.00 g) and lithium hydroxide monohydrate (0.143 g) in water (9.0 mL) was added and then transferred to room temperature for 10 min. Water (100 mL) and ethyl acetate (100 mL) were added to the reaction mixture, and the layers were separated, the organic layer was evaporated, the aqueous layer was adjusted to pH 2 with concentrated hydrochloric acid, and extracted with ethyl acetate (2*100 mL).
- Step C N,N-dimethylformamide (3.0 mL), 2-(4-(ethoxycarbonyl)-5-(methoxymethyl)-1-methyl-, was added sequentially to the reaction flask.
- 1H-pyrrol-2-yl)-2-oxoacetic acid 100 mg
- HATU 184 mg
- DIPEA 106 mg
- S -1,1,1-trifluoropropan-2-amine hydrochloride
- Step D In a reaction flask, MeOH (5.0 mL), (S)-2-(methoxymethyl)-1-methyl-5-(2-oxo-2-(1,1, Ethyl 1-trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylate (150 mg), a solution of sodium hydroxide (33 mg) in water (5 mL) The reaction was carried out at 80 ° C for 4.0 h.
- Step E To the reaction flask, add toluene (10 mL), (S)-2-(methoxymethyl)-1-methyl-5-(2-oxo-2-((1,1,1) -Trifluoropropan-2-yl)amino)acetyl)-1H-pyrrole-3-carboxylic acid (250 mg), thionyl chloride (1.84 g), heated to 115 ° C for 1.0 h under nitrogen, reaction After the completion, the mixture was cooled to room temperature, and the solvent was evaporated to dryness vacuo.
- the acid chloride intermediate (297 mg) was dissolved in N,N-dimethylacetamide (5 mL) at room temperature, and 5-amino-2-fluorobenzonitrile (100 mg) was added to the system, and the mixture was heated to 100 ° C for 0.5 h. . After the reaction was completed, the mixture was cooled to room temperature, and ethyl acetate (2*50 mL) was evaporated.
- Step A In an ice bath, under N 2 protection, 2-chloro-2-oxoacetate (40.8 g) and zinc oxide (1.22 g) were sequentially added to the reaction flask, followed by 2,4-dimethyl- Ethyl 1H-pyrrole-3-carboxylate (5 g) was added. After the addition was completed, the mixture was stirred for 10 minutes in an ice bath, and the ice bath was removed and stirred at room temperature. At the end of the reaction, the reaction mixture was slowly added dropwise to a mixture of 200 mL of ice-water mixture, EA (200 mL) was added, and the organic layer was dried over anhydrous sodium sulfate. Ethyl 2-oxoacetyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate (4.5 g). MS (ESI+, [M+Na] + ) m/z: 290.
- Step B In the reaction flask, ethyl 5-(2-ethoxy-2-oxoacetyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate (3.5 g), MeOH (40 mL), a solution of sodium hydroxide (1.05 g) in water (20 mL) was added dropwise under ice bath, and stirred at room temperature. After completion of the reaction, the pH of the aqueous phase was adjusted to 3-4 with 2N aqueous hydrochloric acid, and then extracted with EA (100 mL*2). The organic phase was washed with water (30mL) and concentrated to give 2-(4-(ethoxycarbonyl)-3. 5-Dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (2.7 g). MS (ESI-, [MH] - ) m/z: 238.1.
- Step C Add 2-(4-(ethoxycarbonyl)-3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoacetic acid (1 g) to the reaction flask at room temperature. , DMF (20 mL), HATU (2.07 g) and DIPEA (1.08 g), after the addition was completed, stirred at room temperature for 10 minutes, and (S)-1,1,1-trifluoropropane-2-hydrochloride (0.63 g) was added. ).
- Step D In the reaction flask, (S)-2,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoropropan-2-yl)amino)acetyl group was added. Ethyl-1H-pyrrole-3-carboxylate (300 mg), MeOH (2 mL), EtOAc (EtOAc) (EtOAc) The reaction was completed, concentrated, and then water (20 mL) and EA (60 mL) was added, the aqueous layer was separated, the organic phase was washed with water (30 mL), and the layers were separated, and the aqueous phase was combined, and the aqueous phase was adjusted with 2N hydrochloric acid to give a pH of about 3.
- Step E sequentially add (S)-2,4-dimethyl-5-(2-oxo-2-((1,1,1-trifluoroprop-2-yl)) to the reaction flask at room temperature.
- Amino)acetyl)-1H-pyrrole-3-carboxylic acid 230 mg
- DMF 5 mL
- HATU 428 mg
- DIPEA DIPEA (194 mg)
- Step A N,N-dimethylformamide (150 mL), 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (10.0 g), iodine was added to the reaction flask under nitrogen. Methane-d 3 (10.4 g), sodium hydrogen (2.857 g) was added portionwise in an ice bath, and then transferred to room temperature for 1.5 h. After the reaction was completed, it was poured into 500 mL of ice water, and the mixture was evaporated.
- Step B Under nitrogen, add tetrahydrofuran (100 mL), 2,4-dimethyl-1-(methyl-d 3 )-1H-pyrrole-3-carboxylic acid ethyl ester (9.50 g). 5-Amino-2-fluorobenzonitrile (8.7g), slowly added dropwise bis(trimethylsilyl)amide lithium (21.5g, 129mL tetrahydrofuran solution) under ice bath, and then transferred to room temperature for 4.0h. . After the reaction was completed, it was slowly poured into 600 mL of ice water and quenched.
- Step C (Compound IV) Under nitrogen atmosphere, add zinc oxide (1.48g), monoethyl chloroacetonate (100g) to the reaction flask under ice bath, stir for 5 minutes, then add N-(3-cyanide in portions). 4-fluorophenyl)-2,4-dimethyl-1-(methyl-d 3 )-1H-pyrrole-3-carboxamide (10.0 g) was added and the mixture was transferred to room temperature for 3.0 h. After the reaction was completed, it was poured into 400 mL of ice water, and the mixture was evaporated, evaporated, evaporated, evaporated, evaporated.
- Step D To the reaction flask, 2-(4-((3-cyano-4-fluorophenyl)carbamoyl)-3,5-dimethyl-1-(methyl-d 3 )- 1H-pyrrol-2-yl)-2-oxoacetate (4.5 g), tetrahydrofuran (35 mL), and a solution of lithium hydroxide monohydrate (1.02 g) in water (50 mL). After the addition, the mixture was transferred to room temperature for 0.2 h. Water (40 mL) and dichloromethane (50 mL) were added to the mixture, and the layers were separated, and the organic layer was evaporated.
- Step E Nitrogen protection and ice bath, adding N,N-dimethylformamide (50 mL), 2-(4-((3-cyano-4-fluorophenyl)carbamoyl) -3,5-Dimethyl-1-(methyl-d 3 )-1H-pyrrol-2-yl)-2-oxoacetic acid (3.8 g), 2-(7-oxobenzotriazole) -N,N,N',N'-tetramethyluronium hexafluorophosphate (5.4 g), (S)-1,1,1-trifluoropropan-2-amine hydrochloride (1.96 g), After stirring for 2 minutes, N,N-diisopropylethylamine (3.2 g) was added.
- N,N-diisopropylethylamine 3.2 g
- Each tube was first prepared with a total volume of 450 ⁇ L of substrate and enzyme mixture and NADPH preincubated at 37 ° C for 5 min, then 50 ⁇ L of NADPH + MgCl 2 mixed solution was added, and 50 ⁇ L of ice acetonitrile containing internal standard was taken out at 30 min. The reaction was stopped at 300 ⁇ L. In addition, 500 ⁇ L of each of the 2 blank groups were added in parallel, and NADPH was not added as a negative control group.
- Sample preparation 50 ⁇ L of incubation sample, 300 ⁇ L of internal standard ice acetonitrile precipitation, vortexing for 5 min, centrifugation (12000 rpm, 4 ° C) for 10 min. Aspirate 75 ⁇ L of the supernatant, add 75 ⁇ L of ultrapure water, dilute and mix, and analyze with 1 ⁇ L of injection. The results are shown in Table 4.
- Plasma sample preparation 495 ⁇ L of blank plasma of corresponding species (mouse, rat, dog, monkey and human) were taken, and 5 ⁇ L of the corresponding test compound solution or positive control was added to obtain a plasma sample solution, so that the plasma drug concentration of the compound was respectively It was 1 ⁇ M, 10 ⁇ M (formulated in acetonitrile).
- Sample preparation 50 ⁇ L of plasma side sample, 450 ⁇ L of internal standard ice acetonitrile was added, vortexed for 5 min, and centrifuged (12000 rpm, 4 ° C) for 10 min.
- Aspirate 75 ⁇ L of the supernatant add 75 ⁇ L of ultrapure water, dilute and mix, and analyze with 1 ⁇ L of the sample;
- 50 ⁇ L of the PBS side sample add 250 ⁇ L of ice-acetonitrile precipitate containing internal standard, vortex for 5 min, and centrifuge (12000 rpm, 4 ° C) for 10 min.
- Pipette 75 ⁇ L of the supernatant add 75 ⁇ L of ultrapure water, dilute and mix, and analyze by 2 ⁇ L. The results are shown in Table 5.
- 300 ⁇ L of the final incubation system contained 30 ⁇ L of liver microsomes (protein concentration: 0.15 mg/mL), 30 ⁇ L of NADPH + MgCl 2 , 3 ⁇ L of substrate (acetonitrile), and 237 ⁇ L of PBS buffer. 2 copies of each species, 0.3 mL per serving.
- Each tube was first prepared with a total volume of 270 ⁇ L of substrate and enzyme mixture, and NADPH was preincubated at 37 ° C for 5 min, then added with 30 ⁇ L of NADPH + MgCl 2 mixed solution, respectively at 0, 10, 30, 60 min. 50 ⁇ L of the reaction was stopped with 300 ⁇ L of ice-acetonitrile containing an internal standard.
- Sample preparation 50 ⁇ L of incubation sample, 300 ⁇ L of ice-acetonitrile containing internal standard diazepam, vortexing for 5 min, centrifugation (12000 rpm, 4 ° C) for 10 min. 75 ⁇ L of the supernatant was aspirated into a 96-well plate and diluted with 75 ⁇ L of ultrapure water, and 0.5 ⁇ L was injected for LC-MS/MS analysis. The results are shown in Tables 6-1, 6-2, 6-3 below.
- Example number 60min remaining amount (%) Example number 60min remaining amount (%) 1 69 12 78.8 6 79.1 29 99.6 7 83.8 42 102 8 70.6 45 73
- Example number 60min remaining amount (%) Example number 60min remaining amount (%) 1 44 12 65.0 6 74.9 17 44.9 7 70.5 25 52.0 8 52.0 29 88.7 11 56.8 42 85.3 45 47
- Example number 60min remaining amount (%)
- Example number 60min remaining amount (%) 6 55 17 47.4 7 81.6 25 50.8 11 47.7 29 99.2 12 67.1 42 61.9
- Example number Solubility ( ⁇ M) Example number Solubility ( ⁇ M) 2 22.1 9 9.6 6 81.8 11 7.5 7 19.8 12 8.1 8 80.9 15 4.9
- mice Male C57BL/6 mice, 6-8 weeks old, were injected with rAAV8-1.3 HBV virus (adr subtype) into C57BL/6 mice at a dose of 1 ⁇ 10 11 vg. At the 2nd and 4th week after the injection of the virus, the mice were bled with blood, and the serum was separated. The expression levels of HBeAg and HBsAg in the serum and the copy number of HBV DNA were determined to judge whether the model was successfully constructed or not.
- the selected HBV DNA expression levels of the mice were greater than 1 ⁇ 10 4 IU / mL, HBeAg greater than 1 ⁇ 10 3 NCU / mL and HBsAg greater than 1 ⁇ 10 3 Ng/mL.
- the mice were divided into groups, and a blank control group, a vehicle control group, and a test group were set. Each group of mice was administered by gavage for 2-3 weeks, once a day. During the experiment, blood was collected from the eyelids every other week, serum was separated, and the DNA content was detected by fluorescent quantitative PCR.
- mice Male C57BL/6 mice aged 6-8 weeks were used, and the purified recombinant plasmid pHBV1.3 (10 ⁇ g) was dissolved in PBS. Each mouse was injected in a volume of about 10% of its body weight through the tail vein at 3-8 s. Injection into mice. After 24 hours of injection of the plasmid, serum HBV DNA was taken from the eyelids, and the serum DNA of the model mice was selected and grouped into a blank control group, a vehicle control group, and a test group. Each group of mice was administered by intragastric administration for 6 days, once a day, at a dose of 30 mg/kg. The mouse serum was taken at 1, 3, 5, and 7 days after the injection, and the liver tissue samples were taken from the 7th day. The HBV DNA copy number in the serum and liver of the mice was detected by real-time quantitative PCR. The results are shown in Table 9.
- ICR mice weighing 18-20 g, were adapted to 3 to 5 days, and were randomly divided into groups of 3, each of which was intragastrically administered at a dose of 30 mg/kg.
- test animals ICR mice
- the test animals were fasted for 12 h before administration, and given food for 4 h after administration. Drinking water was free before and after the experiment and during the experiment.
- the time of blood collection is 0.25h, 3h, 8h
- the time of blood collection is 0.25h, 1h, 6h
- SD rats weighing 180-220 g, were adapted to 3 to 5 days, and were randomly divided into groups of 3, each of which was intragastrically administered at a dose of 20 mg/kg.
- test animals SD rats
- the test animals were fasted for 12 h before administration, and given food for 4 h after administration. Drinking water was free before and after the experiment and during the experiment.
- test animals (Beagle dogs) were fasted for 12 h before administration, and given food for 4 h after administration. Drinking water was free before and after the experiment and during the experiment.
- Example number 12 Mode of administration and dosage PO 5mg/kg T max (h) 1.67 C max (ng/mL) 1282 AUC (0-72h) (ng*h/mL) 61881 AUC (0- ⁇ ) (ng*h/mL) 162075 T1/2(h) 105.2 MRT(0-t)(h) 32.9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
实施例编号 | EC50 | 实施例编号 | EC50 | 实施例编号 | EC50 |
1 | B | 6 | B | 11 | A |
2 | A | 7 | A | 12 | A |
3 | C | 8 | A | 13 | A |
4 | B | 9 | A | 14 | B |
5 | B | 10 | B | 15 | A |
20 | B | 26 | C | 32 | A |
21 | B | 27 | B | 34 | B |
22 | B | 28 | B | 35 | A |
23 | A | 29 | A | 36 | A |
24 | A | 30 | B | 37 | A |
25 | A | 31 | A | 50 | C |
38 | A | 45 | B | 54 | B |
39 | A | 46 | B | 55 | B |
42 | B | 47 | A | 60 | A |
实施例编号 | EC50 | 实施例编号 | EC50 | 实施例编号 | EC50 |
1 | B | 12 | A | 23 | A |
2 | A | 15 | B | 24 | A |
6 | B | 16 | A | 25 | A |
7 | B | 17 | B | 26 | C |
8 | A | 20 | C | 27 | B |
9 | B | 21 | C | 29 | B |
11 | A | 22 | B | 30 | A |
38 | A | 45 | A | 54 | A |
39 | A | 46 | A | 55 | B |
42 | A | 47 | A |
实施例编号 | 60min剩余量(%) | 实施例编号 | 60min剩余量(%) |
1 | 69 | 12 | 78.8 |
6 | 79.1 | 29 | 99.6 |
7 | 83.8 | 42 | 102 |
8 | 70.6 | 45 | 73 |
实施例编号 | 60min剩余量(%) | 实施例编号 | 60min剩余量(%) |
1 | 44 | 12 | 65.0 |
6 | 74.9 | 17 | 44.9 |
7 | 70.5 | 25 | 52.0 |
8 | 52.0 | 29 | 88.7 |
11 | 56.8 | 42 | 85.3 |
45 | 47 |
实施例编号 | 60min剩余量(%) | 实施例编号 | 60min剩余量(%) |
6 | 55 | 17 | 47.4 |
7 | 81.6 | 25 | 50.8 |
11 | 47.7 | 29 | 99.2 |
12 | 67.1 | 42 | 61.9 |
实施例编号 | 溶解度(μM) | 实施例编号 | 溶解度(μM) |
2 | 22.1 | 9 | 9.6 |
6 | 81.8 | 11 | 7.5 |
7 | 19.8 | 12 | 8.1 |
8 | 80.9 | 15 | 4.9 |
实施例编号 | 第7天 | 第14天 | 第21天 | 第28天 |
12 | 2.42 | 3.46 | 5.08 | 2.48 |
25 | 1.16 | 1.76 | 2.89 | 1.28 |
实施例编号 | 第5天血清中HBV DNA下降水平(log10) |
12 | 2.17 |
25 | 1.73 |
实施例编号 | 12 |
给药方式及剂量 | PO 5mg/kg |
T max(h) | 1.67 |
C max(ng/mL) | 1282 |
AUC (0-72h)(ng*h/mL) | 61881 |
AUC (0-∞)(ng*h/mL) | 162075 |
T1/2(h) | 105.2 |
MRT(0-t)(h) | 32.9 |
Claims (21)
- 式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中,X和Y各自独立地表示CR 7,所述R 7独立地选自氢、C 3-4环烷基、-CN、氟、氯、溴或C 1-3烷基,所述C 1-3烷基任选地被一个或多个选自氟、氯、溴、C 1-6烷氧基、-OH、-NH 2或-CN的基团取代;环A选自苯基或5-10元杂芳基;R 1、R 2和R 3各自独立地选自氢、氟、氯、溴、-CHF 2、-CH 2F、-CF 3、-CN、C 1-3烷基、-NH 2、C 3-4环烷基、-NHR a或-NR bR c,其中R a、R b、R c分别独立地选自-C(O)C 1-6烷基、C 1-6烷基、-S(O) 2C 1-6烷基、5-10元杂芳基、C 6-10芳基、C 3-6环烷基或3-6元杂环烷基;R 4选自氢、C 1-3烷基或C 3-4环烷基;R 5选自C 1-6烷基、C 2-6烯基、C 2-6炔基、3-7元环烷基或3-7元杂环烷基,所述C 1-6烷基、C 2-6烯基、C 2-6炔基、3-7元环烷基或3-7元杂环烷基任选地被以下基团取代:卤素、3-4元环烷基、3-4元杂环烷基、-OR 8、氧代、-CN、-C(O)OR 8、-SO 2R 8、-C(O)N(R 8) 2或任选地被一个或多个氟、-CN或-OH取代的C 1-3烷基;R 8各自独立地选自氢或C 1-3烷基。
- 如权利要求1所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R a选自-C(O)C 1-3烷基、C 1-3烷基、-S(O) 2C 1-3烷基、5-6元杂芳基、C 6-10芳基、C 3-6环烷基、或3-6元杂环烷基;任选地,R a选自-C(O)C 1-3烷基、C 1-3烷基、或-S(O) 2C 1-3烷基;任选地,R a选自-C(O)CH 3、或-S(O) 2CH 3。
- 如权利要求1或2所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R b、R c各自独立地选自-C(O)C 1-3烷基、C 1-3烷基、-S(O) 2C 1-3烷基、5-6元杂芳基、C 6-10芳基、C 3-6环烷基、或3-6元杂环烷基;任选地,R b、R c各自独立地选自-C(O)C 1-3烷基、C 1-3烷基、或-S(O) 2C 1-3烷基。
- 如权利要求1-3中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:X和Y各自独立地表示CR 7,所述R 7独立地选自氢、氟、氯、溴或C 1-3烷基,所述C 1-3烷基任选地被一个或多个选自氟或C 1-3烷氧基的基团取代;任选地,R 7独立地选自氢、氟、氯、溴或任选地被一个或多个甲氧基取代的C 1-3烷基;任选地,R 7独立地选自氢、氟、氯、溴、-CH 2OCH 3或甲基;任选地,R 7独立地选自氢、氯、溴或甲基。
- 如权利要求1-3中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中X和Y各自独立地表示CR 7,所述R 7独立地选自氢、C3-4环烷基、-CN、氟、氯、溴或任选地被一个或多个氟取代的C1-3烷基;任选地,R 7独立地选自氢、氟、氯、溴或任选地被一个或多个氟取代的C 1-3烷基;任选地,R 7独立地选自氢、氟、氯、溴或C 1-3烷基;任选地,R 7独立地选自氢、氟、氯、溴或甲基。
- 如权利要求1-5中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:环A选自苯基、5元杂芳基、6元杂芳基、7元杂芳基、8元杂芳基、9元杂芳基或10元杂芳基;任选地,环A选自苯基或6元杂芳基;任选地,环A选自苯基或吡啶基;任选地,环A选自苯基;任选地,环A的定义中出现的所述杂芳基含有1或2个N原子。
- 如权利要求1-6中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 1、R 2和R 3各自独立地选自氢、氟、氯、溴、-CHF 2、-CH 2F、-CF 3、-CN、C 1-3烷基、-NH 2或C 3-4环烷基;任选地,R 1、R 2和R 3各自独立地选自氢、氟、氯、溴、-CHF 2、-CH 2F、-CF 3、-CN、C 1-3烷基或C 3-4环烷基;任选地,R 1选自氢、氟、氯、-CHF 2、-CN、-CF 3或甲基;任选地,R 1选自氢或氟。
- 如权利要求1-7中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 2选自氢、氟、氯或溴;任选地,R 2选自氢或氟。
- 如权利要求1-8中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 3选自氢、氟、氯、-CHF 2、-CN、-CF 3、甲基、-NH 2或-NHR a;任选地,R 3选自氢、氟、氯、-CHF 2、-CN、-CF 3、甲基、-NH 2、-NHC(O)CH 3、或-NHS(O) 2CH 3;任选地,R 3选自氢、氟、氯、-CHF 2、-CN、-CF 3、甲基或-NH 2;任选地,R 3选自氢、氟、氯、-CN、甲基或-NH 2。
- 如权利要求1-9中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 1选自氢、氟、氯、-CHF 2、-CN、-CF 3或甲基,并且R 1和R 3中的至少一个是氟或氢。
- 如权利要求1-9中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 1和R 3中的一个选自氢或氟,另一个选自氢、氟、氯、-CHF 2、-CN、-CF 3、甲基或-NH 2;任选地,R 1和R 3中的一个是氢,另一个选自氟、氯、-CHF 2、-CN、-CF 3或甲基;任选地,R 2选自氟、氯或溴,R 1和R 3中的一个是氢,另一个选自氢、氟、氯、-CHF 2、-CN、-CF 3或甲基;任选地,R 2为氟,R 1和R 3中的一个是氢,另一个选自氟、氯或-CN;任选地,R 2为氟,R 1为氢,R 3为-CN或氯;任选地,R 2选自氟,R 1为氢,R 3为-CN。
- 如权利要求1-11中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 4选自氢或C 1-3烷基;任选地,R 4为甲基或氢;任选地,R 4为甲基。
- 如权利要求1-12中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中:R 5选自C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,所述C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:卤素、3-4元环烷基、3-4元杂环烷基、-OR 8、氧代、-CN、-C(O)OR 8、-SO 2R 8、-C(O)N(R 8) 2或任选地被一个或多个氟、-CN或-OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4烯基、C 2-4炔基、4-6元环烷基或4-6元杂环烷基,其中所述C 1-4烷基、C 2-4烯基、C 2-4炔基、4-6元环烷基或4-6元杂环烷基任选地被选自以下基团取代:卤素、3-4元环烷基、3-4元杂环烷基、-OR 8、氧代、-CN、-C(O)OR 8、-SO 2R 8、-C(O)N(R 8) 2或任选地被一个或多个氟、-CN、-OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,所述C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:卤素、氧代、-OH、-CN、-C(O)OR 8、-C(O)N(R 8) 2或任选地被一个或多个氟或OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,所述C 1-4烷基、C 2-4烯基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:卤素、-OH、-CN、-C(O)OR 8、-C(O)N(R 8) 2或任选地被一个或多个氟或OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4烯基、C 2-4炔基、4-6元环烷基或4-6元杂环烷基,其中C 1-4烷基、C 2-4烯基、C 2-4炔基、4-6元环烷基或4-6元环烷基任选地被选自以下基团取代:卤素、-OH、-CN、-C(O)OR 8、-C(O)N(R 8) 2或任选地被一个或多个氟或OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,所述C 1-4烷基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基任选地被选自以下基团取代:卤素、氧代、-OH、-C(O)N(R 8) 2、-C(O)OR 8或任选被一个或多个OH或氟取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,所述C 1-4烷基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基任选地被选自以下基团取代:卤素、-OH、-C(O)N(R 8) 2、-C(O)OR 8或任选被OH或氟取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、4-6元环烷基或4-6元杂环烷基,其中C 1-4烷基、C 2-4炔基、4-6元环烷基或4-6元杂环烷基任选地被选自以下基团取代:卤素、-OH、-C(O)OR 8或任选被OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、3-6元环烷基或4-6元杂环烷基,其中所述C 1-4烷基任选地被以下基团取代:卤素、-OH或-C(O)OR 8,其中所述3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:氧代、-OH、氟、-C(O)N(R 8) 2或任选被一个或多个OH或氟取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、3-6元环烷基、4-6元杂环烷基,其中所述C 1-4烷基任选地被以下基团取代:卤素、-OH或-C(O)OR 8,其中所述3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:-OH、氟、-C(O)N(R 8) 2或任选被OH或氟取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 2-4炔基、4-6元环烷基、4-6元杂环烷基,其中C 1-4烷基任选地被选自以下基团取代:卤素、-OH或-C(O)OR 8,其中4-6元环烷基、4-6元杂环烷基任选地被选自以下基团取代:-OH或任选被OH取代的C 1-3烷基;任选地,R 5选自C 1-4烷基、C 3炔基、3-6元环烷基或4-6元杂环烷基,其中所述C 1-4烷基任选地被以下基团取代:氟、-OH或-C(O)OCH 3,其中所述3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:氧代、-OH、氟、-C(O)NHCH 3或任选被一个或多个OH或氟取代的甲基;任选地,R 5选自C 1-4烷基、C 3炔基、3-6元环烷基、4-6元杂环烷基,其中所述C 1-4烷基任选地被以下基团取代:氟、-OH或-C(O)OCH 3,其中所述3-6元环烷基或4-6元杂环烷基任选地被以下基团取代:-OH、氟、-C(O)NHCH 3或任选被OH或氟取代的甲基;任选地,R 5的定义中出现的所述杂环烷基含有1或2个选自N、O或S的杂原子。
- 如权利要求1-13中任一项所述的式I化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,其中R 8选自氢或甲基。
- 药物组合物,其包含如权利要求1-19中任一项所述的化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐;任选地,所述药物组合物还包含药学上可接受的辅料。
- 如权利要求1-19中任一项所述的化合物、其立体异构体、互变异构体、几何异构体、溶剂化物、活性代谢物、水合物、前药或药学上可接受的盐,或者如权利要求20所述的药物组合物在制备用于预防或者治疗受益于衣壳蛋白装配抑制的疾病的药物中的用途。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211543931.7A CN115974753A (zh) | 2018-03-30 | 2019-03-29 | 含有n杂五元环化合物和用途 |
US17/043,593 US11597716B2 (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
JP2020552331A JP7434166B2 (ja) | 2018-03-30 | 2019-03-29 | N-複素環式5員環含有カプシドタンパク質のアセンブリの阻害剤、その医薬組成物および使用 |
CN202211627236.9A CN115974754A (zh) | 2018-03-30 | 2019-03-29 | 含有n杂五元环化合物和用途 |
AU2019241321A AU2019241321B2 (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
SG11202009150RA SG11202009150RA (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
CA3094022A CA3094022A1 (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
KR1020207031226A KR20200136994A (ko) | 2018-03-30 | 2019-03-29 | N-헤테로시클릭 5-원 고리-함유 캡시드 단백질 조립 억제제, 그의 약학적 조성물, 및 그의 용도 |
EA202092159A EA202092159A1 (ru) | 2019-01-25 | 2019-03-29 | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение |
EP19777163.7A EP3778569A4 (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
CN201980021317.4A CN111868026B (zh) | 2018-03-30 | 2019-03-29 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
PH12020551616A PH12020551616A1 (en) | 2018-03-30 | 2020-09-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
ZA2020/06378A ZA202006378B (en) | 2018-03-30 | 2020-10-14 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
US18/106,103 US20230183208A1 (en) | 2018-03-30 | 2023-02-06 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
AU2023204386A AU2023204386A1 (en) | 2018-03-30 | 2023-07-07 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810286111 | 2018-03-30 | ||
CN201810286111.1 | 2018-03-30 | ||
CN201810730325.3 | 2018-07-05 | ||
CN201810730325 | 2018-07-05 | ||
CN201910073465 | 2019-01-25 | ||
CN201910073465.2 | 2019-01-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/043,593 A-371-Of-International US11597716B2 (en) | 2018-03-30 | 2019-03-29 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
US18/106,103 Continuation US20230183208A1 (en) | 2018-03-30 | 2023-02-06 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019185016A1 true WO2019185016A1 (zh) | 2019-10-03 |
Family
ID=68058571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/080412 WO2019185016A1 (zh) | 2018-03-30 | 2019-03-29 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11597716B2 (zh) |
EP (1) | EP3778569A4 (zh) |
JP (1) | JP7434166B2 (zh) |
KR (1) | KR20200136994A (zh) |
CN (3) | CN115974754A (zh) |
AU (2) | AU2019241321B2 (zh) |
CA (1) | CA3094022A1 (zh) |
PH (1) | PH12020551616A1 (zh) |
SG (1) | SG11202009150RA (zh) |
WO (1) | WO2019185016A1 (zh) |
ZA (1) | ZA202006378B (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10590076B2 (en) | 2018-06-11 | 2020-03-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
WO2020151252A1 (zh) * | 2019-01-25 | 2020-07-30 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
WO2021058002A1 (zh) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用 |
WO2021058001A1 (zh) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | N杂五元环化合物的晶型及其应用 |
US11008346B2 (en) | 2014-06-11 | 2021-05-18 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2021093172A1 (zh) | 2019-11-13 | 2021-05-20 | 西安新通药物研究有限公司 | Hbv抑制剂及其用途 |
WO2021119081A1 (en) * | 2019-12-10 | 2021-06-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
CN113365999A (zh) * | 2019-01-31 | 2021-09-07 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
WO2021197486A1 (zh) * | 2020-04-03 | 2021-10-07 | 东莞市东阳光新药研发有限公司 | 新型螺环类化合物及其在药物中的应用 |
JP2022508642A (ja) * | 2018-10-05 | 2022-01-19 | エモリー ユニバーシティ | モノマーおよびマルチマー抗hbv薬 |
US11247965B2 (en) | 2017-12-11 | 2022-02-15 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11597716B2 (en) | 2018-03-30 | 2023-03-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
WO2023056933A1 (zh) | 2021-10-08 | 2023-04-13 | 正大天晴药业集团股份有限公司 | 包含衣壳蛋白抑制剂和逆转录酶抑制剂的药物组合 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3805223A4 (en) | 2018-05-25 | 2021-12-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2,3-DIHYDRO-1H-PYRROLIZIN-7-FORMAMIDE DERIVATIVE AND USE OF IT |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014184350A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
CN105658624A (zh) * | 2013-10-23 | 2016-06-08 | 爱尔兰詹森科学公司 | 甲酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
WO2017156255A1 (en) | 2016-03-09 | 2017-09-14 | Emory University | Elimination of hepatitis b virus with antiviral agents |
CN107721895A (zh) * | 2017-10-13 | 2018-02-23 | 天津科技大学 | 新型五取代2,3‑二氢吡咯衍生物及其制备方法和应用 |
WO2018039531A1 (en) * | 2016-08-26 | 2018-03-01 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2018050110A1 (zh) | 2016-09-18 | 2018-03-22 | 正大天晴药业集团股份有限公司 | 新型衣壳蛋白装配抑制剂 |
WO2019154343A1 (zh) | 2018-02-09 | 2019-08-15 | 正大天晴药业集团股份有限公司 | 衣壳蛋白装配抑制剂、其药物组合物和用途 |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
JP7434166B2 (ja) | 2018-03-30 | 2024-02-20 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | N-複素環式5員環含有カプシドタンパク質のアセンブリの阻害剤、その医薬組成物および使用 |
EP3805223A4 (en) | 2018-05-25 | 2021-12-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2,3-DIHYDRO-1H-PYRROLIZIN-7-FORMAMIDE DERIVATIVE AND USE OF IT |
SG11202012346YA (en) | 2018-06-11 | 2021-01-28 | Venatorx Pharmaceuticals Inc | Hepatitis b capsid assembly modulators |
EA202092159A1 (ru) | 2019-01-25 | 2020-12-15 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение |
CN113365999B (zh) | 2019-01-31 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
EP4036078A4 (en) | 2019-09-29 | 2023-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CRYSTAL FORM OF A FIVE-MEMBERED RING CAPSID PROTEIN ASSEMBLY INHIBITOR WITH N AS A HETEROATOM, AND APPLICATION THEREOF |
WO2021058001A1 (zh) | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | N杂五元环化合物的晶型及其应用 |
-
2019
- 2019-03-29 JP JP2020552331A patent/JP7434166B2/ja active Active
- 2019-03-29 KR KR1020207031226A patent/KR20200136994A/ko unknown
- 2019-03-29 CA CA3094022A patent/CA3094022A1/en active Pending
- 2019-03-29 CN CN202211627236.9A patent/CN115974754A/zh active Pending
- 2019-03-29 CN CN201980021317.4A patent/CN111868026B/zh active Active
- 2019-03-29 WO PCT/CN2019/080412 patent/WO2019185016A1/zh active Application Filing
- 2019-03-29 CN CN202211543931.7A patent/CN115974753A/zh active Pending
- 2019-03-29 AU AU2019241321A patent/AU2019241321B2/en active Active
- 2019-03-29 US US17/043,593 patent/US11597716B2/en active Active
- 2019-03-29 SG SG11202009150RA patent/SG11202009150RA/en unknown
- 2019-03-29 EP EP19777163.7A patent/EP3778569A4/en active Pending
-
2020
- 2020-09-29 PH PH12020551616A patent/PH12020551616A1/en unknown
- 2020-10-14 ZA ZA2020/06378A patent/ZA202006378B/en unknown
-
2023
- 2023-02-06 US US18/106,103 patent/US20230183208A1/en active Pending
- 2023-07-07 AU AU2023204386A patent/AU2023204386A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014184350A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015011281A1 (en) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
CN105431413A (zh) * | 2013-07-25 | 2016-03-23 | 爱尔兰詹森科学公司 | 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
CN105658624A (zh) * | 2013-10-23 | 2016-06-08 | 爱尔兰詹森科学公司 | 甲酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
WO2017156255A1 (en) | 2016-03-09 | 2017-09-14 | Emory University | Elimination of hepatitis b virus with antiviral agents |
WO2018039531A1 (en) * | 2016-08-26 | 2018-03-01 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
CN107721895A (zh) * | 2017-10-13 | 2018-02-23 | 天津科技大学 | 新型五取代2,3‑二氢吡咯衍生物及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
"Greene's Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC. |
MAYUR BRAHMANIA ET AL., NEW THERAPEUTIC AGENTS FOR CHRONIC HEPATITIS B |
See also references of EP3778569A4 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11008346B2 (en) | 2014-06-11 | 2021-05-18 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11247965B2 (en) | 2017-12-11 | 2022-02-15 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
US11597716B2 (en) | 2018-03-30 | 2023-03-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof |
US11014881B2 (en) | 2018-06-11 | 2021-05-25 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
US10590076B2 (en) | 2018-06-11 | 2020-03-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
US11566001B2 (en) | 2018-06-11 | 2023-01-31 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B capsid assembly modulators |
JP2022508642A (ja) * | 2018-10-05 | 2022-01-19 | エモリー ユニバーシティ | モノマーおよびマルチマー抗hbv薬 |
WO2020151252A1 (zh) * | 2019-01-25 | 2020-07-30 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
AU2019424375B2 (en) * | 2019-01-25 | 2023-07-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof |
CN113365999A (zh) * | 2019-01-31 | 2021-09-07 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
CN113365999B (zh) * | 2019-01-31 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
CN114430736A (zh) * | 2019-09-29 | 2022-05-03 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用 |
WO2021058002A1 (zh) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用 |
WO2021058001A1 (zh) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | N杂五元环化合物的晶型及其应用 |
JP2022522522A (ja) * | 2019-11-13 | 2022-04-19 | 西安新通薬物研究股▲フン▼有限公司 | Hbv抑制剤及びその用途 |
WO2021093172A1 (zh) | 2019-11-13 | 2021-05-20 | 西安新通药物研究有限公司 | Hbv抑制剂及其用途 |
JP7285027B2 (ja) | 2019-11-13 | 2023-06-01 | 西安新通薬物研究股▲フン▼有限公司 | 化合物、その薬学的に許容される塩又は立体異性体、その使用、及び薬物組成物 |
EP4245372A2 (en) | 2019-11-13 | 2023-09-20 | Xi'An Xintong Pharmaceutical Research Co., Ltd. | Hbv inhibitor and use thereof |
US11903924B2 (en) | 2019-11-13 | 2024-02-20 | Xi'an Xintong Pharmaceutical Research Co., Ltd. | HBV inhibitor and its use |
WO2021119081A1 (en) * | 2019-12-10 | 2021-06-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
CN113493441A (zh) * | 2020-04-03 | 2021-10-12 | 广东东阳光药业有限公司 | 新型螺环类化合物及其在药物中的应用 |
WO2021197486A1 (zh) * | 2020-04-03 | 2021-10-07 | 东莞市东阳光新药研发有限公司 | 新型螺环类化合物及其在药物中的应用 |
WO2023056933A1 (zh) | 2021-10-08 | 2023-04-13 | 正大天晴药业集团股份有限公司 | 包含衣壳蛋白抑制剂和逆转录酶抑制剂的药物组合 |
Also Published As
Publication number | Publication date |
---|---|
CN115974754A (zh) | 2023-04-18 |
ZA202006378B (en) | 2024-02-28 |
KR20200136994A (ko) | 2020-12-08 |
AU2019241321A1 (en) | 2020-10-08 |
SG11202009150RA (en) | 2020-10-29 |
PH12020551616A1 (en) | 2021-08-16 |
US20230183208A1 (en) | 2023-06-15 |
JP7434166B2 (ja) | 2024-02-20 |
US20210017154A1 (en) | 2021-01-21 |
EP3778569A4 (en) | 2021-12-29 |
AU2019241321B2 (en) | 2023-04-13 |
US11597716B2 (en) | 2023-03-07 |
JP2021519325A (ja) | 2021-08-10 |
CN111868026B (zh) | 2022-11-25 |
AU2023204386A1 (en) | 2023-08-03 |
CN111868026A (zh) | 2020-10-30 |
CA3094022A1 (en) | 2019-10-03 |
EP3778569A1 (en) | 2021-02-17 |
CN115974753A (zh) | 2023-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019185016A1 (zh) | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 | |
JP6553748B2 (ja) | 縮合環化合物、医薬組成物およびその使用 | |
WO2020177653A1 (zh) | 吡嗪类衍生物及其在抑制shp2中的应用 | |
CN1060768C (zh) | 吡唑和吡唑并嘧啶 | |
JP4155598B2 (ja) | 抗癌剤としての縮合n−アシルインドール | |
WO2020011246A1 (zh) | 含苯环的化合物、其制备方法及应用 | |
US20050009775A1 (en) | Nucleoside compounds in hcv | |
CN109311891B (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
TW202045499A (zh) | 用於治療hbv感染或hbv誘發疾病之醯胺衍生物 | |
CN111601788B (zh) | 衣壳蛋白装配抑制剂、其药物组合物和用途 | |
JP7479384B2 (ja) | N-複素環式5員環含有カプシドタンパク質のアセンブリの阻害剤、その医薬組成物および使用 | |
WO2019029521A1 (zh) | 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 | |
CN109071548A (zh) | 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物 | |
WO2020156494A1 (zh) | 含有吡咯并杂环的衣壳蛋白装配抑制剂 | |
JP2022549923A (ja) | Nヘテロ五員環含有カプシドタンパク質集合阻害剤の結晶形及びその使用 | |
JP2013519693A (ja) | Hiv複製の阻害薬としての1−フェニル−1,5−ジヒドロ−ベンゾ[b][1.4]ジアゼピン−2.4−ジオンの誘導体 | |
WO2024032747A1 (zh) | 三环类化合物及其医药用途 | |
CN115677684A (zh) | 取代芳基或杂芳基类化合物 | |
EA043039B1 (ru) | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение | |
CN113795486A (zh) | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 | |
WO2023236752A1 (zh) | 一种杂环衍生物及其药物组合物、应用 | |
CN115677664A (zh) | 作为parp7抑制剂的哒嗪酮类化合物 | |
WO2022166761A1 (zh) | 噻吩并嘧啶衍生物 | |
CN113748111A (zh) | 具有抗乙型肝炎病毒(hbv)活性的新型草酰哌嗪类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19777163 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3094022 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020552331 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019241321 Country of ref document: AU Date of ref document: 20190329 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207031226 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019777163 Country of ref document: EP |